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CHAPTER 1
INTRODUCTION

Malignant cells commonly exhibit increased activity
of several degradative enzymes that are believed to
contribute to their invasive and metastatic potential. Of
special interest in this regard are proteases such as
cathepsin B and L, and urine-type plasminogen activator
(uPA). However, little is known about the pattern of
protease gene expressions caused by different oncogene
transformation.
Non-transformed NIH 3T3 and NIH 3T3 murine
fibroblasts transfected with 4 different ras oncogene
constructs have been characterized with respect to their
metastatic potential in nude mice. The PC3-P and PC3-M cell
lines are human prostate carcinoma cell lines with a
different metastatic potential. A375-P & A375-M cells lines
are derived from a human melanoma with a different
metastatic potential.
Tumor promoting phorbol esters such as phorbol-12myristate-13-acetate (PMA) are diacylglycerol (DAG) analogs
which directly stimulate the phospholipid-dependent protein
kinase C (PKC). Studies on the effects of the potent tumor
promoter (PMA) have demonstrated that it induces a highly
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pleiotropic response in a variety of cell lines, including a
more metastatic phenotype, and increased expression of
several different proteases and protease inhibitors.
However, it is not known whether the cellular response to
phorbol esters differs among tumor cells with different
oncogene transformation and metastatic potentials. There
were three specific aims of this project:
(1) To explore the mechanism by which oncogenes
induce the metastatic phenotype by studying protease gene
induction and regulation by ras oncogenes.
(2) To determine how exogenous signal factors
regulate protease and protease inhibitor expressions in
transformed and metastastic cells.
The results of this project may contribute to the
understanding of the complexity of proteases expression and
involvement in tumor metastasis.

Chapter I I

REVIEW OF THE LITERATURE

Tumor Metastasis and Proteases

Malignant tumors differ from benign tumors in their
ability to spread throughout the body, giving rise to
metastases at sites distant from the primary tumor.
Metastasis is a complex process involving many steps, each
has its own regulatory mechanism (Foste, G. and Fidler, J.
J., 1980). However, from a simple point of view, the

following types of invasive and degradative processes must
occur in order for a secondary tumor to be established. A
cell must break away from the primary tumor mass, penetrate
the tissues surrounding the tumor, and move through the
cellular layers and basement membrane of blood and lymph
vessels in order to enter the circulatory system. Tumor
cells are then disseminated by the blood and lymphatic
circulation. Subsequently, they must extravasate from the
circulation and reach a site favorable for proliferation.
The result of the process is the formation of a new tumor.
It has been recognized for many years that a positive
3

'"'"""'"
4

correlation exists between cellular invasion and proteinase
production, and it has been hypothesized that proteolytic
activity may, in fact, be required for invasiveness.
According to this theory, cells are invasive by virtue of
their ability to secrete (or induce secretion of)
proteinases capable of degrading the molecules which compose
the barriers they must cross. These barriers include
basement membrane, interstitial tissue and extracellular
matrices, which are composed primarily of collagen,
proteoglycan, elastin and other glycoproteins.
Considerable evidence has amassed suggesting that a
number of proteinases capable of degrading the molecular
barriers are associated with transformed cells. The best
characterized or identified enzymes are urokinase-type
plasminogen activator (uPA), type IV collagenases,
stromelysin, and cathepsin B-like and cathepsin L-like
proteinases.

Biochemistry of Plasminogen Activators

One of the most studied wide-spectrum proteinase is
the serine protease plasmin. Plasmin is able to dissolve
fibrin clots, digest extracellular matrix proteins, and
activate latent enzymes and hormones (Mullins and Rohrlich,
1983). It is formed by the proteolytic cleavage of the
abundant proenzyme plasminogen. Plasminogen is a 791 amino
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acid zymogen which is activated to the broad-specificity
protease plasmin by a single proteolytic cleavage at Arg560. The reaction is mainly catalyzed by two molecularly
different, functionally similar, enzymes called plasminogen
activators (PAs), urokinase-type plasminogen activator (uPA)
and tissue-type plasminogen activator (t-PA). Both are
widely distributed in body fluids and tissues, but uPA is
more abundant in urine while t-PA is more abundant in plasma
(Blasi, et al., 1987). They participate in the regulation of
several physiological processes by initiating a reaction
leading to the formation of active plasmin. t-PA is regarded
as an important mediator of the fibrinolytic activity in
circulation. u-PA has a role in

cellular invasion and

tissue involution (Beer et al., 1975), cellular migratory
activity (Vassalli, et al., 1976), trophoblast implantation
(Strickland et al., 1976), and mammary gland involution
(Ossowski et al., 1979), tumor invasion and metastasis
(Ossowski and Reich, 1983), and a variety of other
physiological processes.

Structure and Regulation of uPA

The primary structure of uPA has been determined both
by protein sequencing and by deducing the amino acid
sequence from its cloned cDNA. The human uPA is the
translated, active and mature product of a 2.5 kb-long mRNA,
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(Verde et al., 1984) which is transcribed from a 6.5 kb gene
present on the long arm of chromosome 10 (Tripputi et al.,
1985). It is organized in 11 exons and 10 introns (Riccio et
al., 1985). Translation of the mRNA yields a prepro-uPA with
431 amino and with a molecular weight 54 kD. Removal of a 20
residue long signal peptide gives rise to the secreted
single-chain pro-uPA, which is a glycosylated polypeptide
(in human) of about 50 kD (Pennica et al., 1983). Mouse uPA, however, contains no N-glycosylation site (Belin et al.,
1985). It is this pro-uPA that is released from a variety of
cultured normal and neoplastic cell types, and appears to be
the predominant extracellular form of u-PA in the organism
(Dano, et al., 1985). The single-chain uPA is considered a
proenzyme form that has little or no proteolytic activity
against the natural substrate plasminogen, and no activity
against synthetic plasminogen activator substrates. Singlechain uPA is converted into an active two chain form with Mr
50,000 by proteolytic cleavage after lysine-158, resulting
in two polypeptide chains held together by one disulfide
bond (Guenzler et al., 1982)

This conversion can be

catalyzed by plasmin (Dano et al., 1985), plasma kallikrein
(Ichinose et al., 1986), factor XIIa (Ichinose et al.,
1986), trypsin (Eaton et al., 1984), and thrombin (Easton et
al., 1984) .
The regulation of uPA production has been reported to
be associated with various compounds such as growth factors
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and the tumor promoter phorbol-12-myristate-13-acetate (PMA)
(Degen et al., 1985; Collart et al., 1986; Bell et al.,
1990). It is increased by epidermal growth factor (EGF)
(Boyd, 1989; Niedbala and Sartorelli, 1989), plateletderived growth factor (PDGF)
interferon (INF-gamma)

(Stoppelli et al., 1986),

(Collart et al., 1986), transforming

growth factor beta (Keski-Oja et al., 1988), vasopressin
(Nagamine et al., 1983) and estrogen (Mira-y-Lopez et al.,
1983). Glucocorticoids have been shown to decrease uPA
production in certain normal and malignant cells (Medcalf et
al, 1986, Busso et al., 1987).

uPA receptor

Several types of cells possess specific high affinity
(Kd

=

10

-io

M) plasma membrane binding sites for uPA. Human

peripheral blood monocytes (Vassalli et al., 1985), the
monocyte-like U937 cells, fibroblasts, and HT1080
fibrosarcoma cells (Testa and Quigley, 1988) all have
approximately 10

5

such specific receptors per cell. The

receptor was shown to be a 55-60 kD glycoprotein (Nielsen et
al., 1988). The region of u-PA that binds the receptor is
located on the 135-residue-long amino terminal fragment
(ATF) of the A-chain of two chain urokinase. More precisely,
the first 32 residues of the "growth factor" region of the
ATF peptide is required for receptor binding. The ATF
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fragment comprises two structural domains, a "growth factor"
region with homology to EGF and a kringle domain (Patthy L.,
1985}. In contrast, the Mr 33,000 KDa form of u-PA, a
partial degradation product of the two chain Mr 50,000
enzyme, lacks the ATF and does not interact with the
receptor. The 33,000 dalton form, however, retains catalytic
activity (Stoppelli et al., 1985). Receptor binding does not
require u-PA catalytic activity, and the single-chain
zymogen u-PA binds with about the same affinity as does the
active Mr 50,000 two-chain enzyme.
The receptor-bound forms of plasminogen activator is
enzymatic active, and binding of either the one-chain and
two-chain u-PA to the u-PA receptor on cultured human
monocytes-macrophage results in the generation of plasminmediated pericellular proteolysis (Dano et al., 1985). Thus
the presence of a u-PA receptor allows cells to acquire
surface-bound plasminogen-activating ability.

Roles of uPA in Neoplasia

The first experiment showing a direct cause-effect
relationship between uPA and metastasis is that performed by
Ossowski and Reich (Ossowski and Reich, 1983). They found
that human HEp3 cells inoculated onto the chorio-allantoic
membrane of a chicken embryo were able to metastasize to the
lung of the embryo and that this process could be blocked by
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specific anti-catalytic antibodies against human uPA.
There are multiple reports of an increase in the
synthesis of uPA in cultured cells transformed by oncogenes
or oncogenic viruses, on treatment of cultured cells with
tumor promoter, and on the assay of transformed tissue in
comparison to surrounding normal tissues (reviewed by Dano
et al., 1985). However there also are a number of reports
showing a lack of correlation or a negative correlation
between uPA activity and ability to metastasize (Harvey et
al., 1988; Graf et al., 1984; Giraldi et al., 1985).
Recently, more direct evidence in support of a role of
urokinase in tumor cell metastasis has come from experiments
in which the expression of the human urokinase sense and
anti-sense genes expressed in murine B16 cells has been
shown to increase or decrease the metastatic potential of
these cells (Yu and Schultz, 1990). Also, the overexpression
of human uPA increases the capacity of ras-transformed
murine NIH 3T3 cells to colonize the nude mouse lung after
tail-vein injection.

(Axelrod et al., 1989).

PA inhibitor

Precise regulation of plasminogen activator (PA)
activity constitutes a critical feature of many biological
processes. This regulation may occur at various levels,
including the synthesis and secretion of PAs, and the
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interaction with specific PA inhibitors, the PAis {Sprengers
and Kluft, 1987). The two most important protease inhibitors
specific for PAs (PAI-1 and PAI-2) have recently been
identified and characterized.
Plasminogen activator inhibitor type 1 {PAI-1) is the
major PAI found in plasma (Kruithof et al., 1983; Thorsen
and Philips, 1984). It has been shown to be expressed in
many body tissues (Quax et al., 1990; Erickson et al.,
1990), the conditioned media of fibrosarcoma cells
(Andreason et al., 1986), hepatocytes {Sprengers et al.,
1985), smooth muscle (Laug, 1987) and melanoma cells (Wagner
and Binder, 1986). It is a 50-kDa glycoprotein, belonging to
the serpin family (Pannekoek et al., 1986; Ny et al., 1986),
and a specific inhibitor of both tissue-type PA and
urokinase-type PA (Kruithof et al., 1984; Kruithof et al.,
1986) .
The biosynthesis of PAI-1 appears to be highly
regulated. For example, PAI-1 synthesis can be induced by
endotoxin {Culucci et al., 1985), inflammatory mediators
(Emeis and Kooistra, 1986; Sawdey et al., 1989),
glucocorticoid {Andreasen et al., 1987), insulin (Kooistra
et al., 1989) and phorbol ester (Mayer et al., 1988).
Plasminogen activator inhibitor type 2 {PAI-2) has
been purified from the human placenta (Kawano et al., 1986)
and epidermis {Astedt et al., 1986)

It is produced by many

cell types including monocyte-macrophage and human
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histiocytic lymphoma cells (Kruithof et al., 1986). The cDNA
cloning and amino acid sequence of PAI-2 have been
determined from human placenta (Ye et al., 1987), human
histiocytic lymphoma cells (Schleuning et al., 1987), and
human monocyte (Wagner and Binder, 1987). PAI-2 consists of
415 amino acids, corresponding to a Mr 47 kD protein. It
exists in two forms, a 47 -kD, pl 5.0, nonglycosylated form
and a 60-kd, pl 4.4, glycosylated form, with similar PA
inhibition characteristics (Genton, et al., 1987; Wohlwend
et al., 1987). Interestingly, in short-term culture, the
nonglycosylated form, representing over 90% of synthesized
PAI-2, is only found intracellularly, whereas the
glycosylated form is secreted (Genton, et al., 1987;
Wohlwend et al., 1987).
The regulation of PAI-2 production in macrophage has
been characterized in some detail. It is decreased by
dexamethasone but increased by the tumor promoter phorbol
myristate acetate (Kruithof et al., 1986; Schleuning, et
al., 1987), endotoxin (Chapman and stone, 1985), and muramyl
dipeptide (Stephens, et al., 1985). In peripheral blood
mononuclear cells lipopolysaccharide increases the release
of PAI-2 leading to an anti-f ibrinolytic state (Schwartz et
al., 1988).

12
structure and Regulation of cathepsin B

cathepsin B is one of most characterized cysteine
proteinase. Cathepsin B has been purified from many
different normal tissues of numerous species. Mature
cathepsin B seems to exist in either a single chain form of
39 kDa or a double chain form of 25 and 5 kDa. The
proportions of the single and double chain forms varying
from species to species. The active site of cathepsin B was
found in the light or 5 kDa chain of the double chain form.
The preprocathepsin B cDNAs have been isolated from
rat (Segundo et al., 1986), mouse (Chan et al., 1986) and
human (Chan et al., 1986). Based on the nucleotide sequence,
cathepsin B is synthesized as a preproenzyme of 339 amino
acids, which consists of a 17 residue prepeptide sequence at
the N-terminus, a 62 residue propeptide sequence, and a 6
residue extension at the carboxyl terminus. The signal
peptide of 17 amino acids in preprocathepsin B is cleaved to
give procathespin B in the endoplasmic reticulum.

The

protein is glycolated in the Golgi complex and, in
nontransformed cells, the majority is transported to
lysosomes through the mannose-6-phosphate signal pathway
(Gal et al., 1985). A defect in this pathway in I-cell
disease results in the release of lysosomal enzymes and the
association of some lysosomal enzymes with small vesicles
near the plasma membrane (van Dongen et al., 1985). A
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similar process may occur in some transformed cells (Archkar
et al., 1989). Within the lysosomal acid compartment,
procathepsin B is processed to the single-chain mature form
of cathepsin B (Steiner et al., 1984).
Using a human cDNA to the cathepsin B as a
hybridization probe, 2.2 and 4.1 kb mRNA species were
detected in Northern blots of normal murine lines and murine
melanomas (Fong et al., 1986). However, Qian reported that
B16 melanoma variants contain 2.2, 4.0 and 5.0 kb mRNA
transcripts for cathepsin B, but normal tissues only contain
the 2.2 kb transcript (Qian et al., 1989; 1991a; 1991b) and
Chambers et al., (1992) have observed a 4.0 kb cathepsin B
mRNA in metastatic ras-transf ormed NIH 3T3 cell but not in
non-metastatic variants. The larger transcripts are thought
to be due to alternative polyadenylation site selection
during the processing of the 3'-end of the cathepsin B mRNA
(Qian et al., 1991a; 1991b). Variant messengers for
Cathepsin B are also found in normal human tissue and
tumors, and these arise as a result of alternative splicing
of the 5 1 and 3 1 levels of the cathepsin B mRNAs (Gong and
Frankfater, personal communication).

Enzymology of cathepsin B

The pH profile for cathepsin B activity is substratedependent. The optimum pH is about 6.0 for synthetic
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substrates such as carbobenzyloxy-L-arginine-L-arginine-2naphthylamide (Z-Arg-Arg-NHMec)
At pH 7.4

(Barret and Kirschke, 1981).

significant activity can be observed for times up

to 12 hours if the assay is performed against large protein
substrates that presumably stabilize the enzyme, provide
resistance to inactivation by cysteine proteinase inhibitors
(CPI) and physiological pH (Rozhin et al., 1987; 1990; Lah
et al., 1989). Natural physiological substrates for
cathepsin B are still a matter of speculation. Laminin,
fibrinogen (Lah et al., 1989), fibronectin (Recklies et al.,
1982), trypsinogen (Figarella et al., 1988) are all degraded
by tumor and liver cathepsin B at both acid and neutral pH
in vitro (Lah et al., 1990; Sloane et al., 1990).

Cathepsin

B has been shown to be able to degrade proteins of the
extracellular matrix including the non-helical regions of
basement membrane type IV collagen, in vitro (Morrison et
al., 1973; Burleigh et al., 1974; reviewed in Sloane and
Honn, 1984).

cathepsin B and Tumor Malignancy

There is an extensive literature on the elevation of
release of cathepsin B from both human and animal tumor
cells in vitro (Sloane and Honn, 1984; Recklies, 1987). It
is reported that a rise of cathepsin B activity was observed
in human malignant breast tumors (Recklies et al., 1980), in
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rat metastatic pancreatic cancer (Koppel et al., 1986), in
murine B16 melanoma (Sloane et al., 1982), in Lewis lung
carcinoma (Sloane et al., 1984), and in a rat sarcoma LW13K2
(Krepela et al., 1989).
Cathepsin B is released into extracellular fluid by
breast tumor cells in organ culture in two major forms, a
latent and an active form, with Mr precursor of 40 kD for
both forms (Mort et al., 1980). The latent form can be
activated with pepsin, resulting in the formation of a 33 kD
active form of cathepsin B. A high Mr (40 kD) active form of
cathepsin B was also reported in culture media of
spontaneous mammary glands (Racklies et al., 1982) and
lactating mammary glands (Recklies and Mort, 1985). The
levels of a latent cathepsin B-like activities secreted by
B16 melanoma variants parallels the metastatic capabilities
of the variants (Qian et al., 1989). In addition, cathepsin
B activity has been associated with the plasma membrane
fractions of various tumor cell lines (Sloane et al., 1987;
Sloane et al., 1986; Rozhin et al., 1990). An
immunof luorescence study showed that the distribution of
cathepsin B in cultured human colon carcinoma cells appears
to be at the cell surface (Maciewixz et al., 1989).
How cathepsin B is released by tumors or how it is
associated with the plasma membrane-enriched fractions is
not clear. It is suggested that either oversaturation of
mannose-6-pathway and/or defects in the mannose-6-pathway
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could be involved in these non-lysosomal localization
(Goldberg et al., 1983; Mainferme et al., 1985; Achkar et
al., 1990; Pracht and Frankfater, unpublished data).

structure of cathepsin L

Cathepsin L, another cysteine protease, is one of
several acid protease-like cathepsins to be involved in the
degradation of polypeptides within the lysosomes (Gottesman,
1978). Full length cDNA clones encoding the entire cathepsin
L precursor molecule have been isolated from both mouse
(Troen et al., 1987; Portnoy et al., 1986; Joseph et al.,
1988) and human cells (Joseph et al., 1988; Gals. and
Gottesman M. M., 1988).
The exact cleavage sites involved in processed forms
of lysosomal cathepsin L have been determined by comparing
actual amino acid sequences of the mature protein and
sequences deduced from the cDNA clones.
Cathepsin L is synthesized as a prepropeptide
containing a hydrophobic signal sequence of 17 amino acids
which is cleaved to give procathepsin L. This protein is
glycosylated in the Golgi complex and, in nontransformed
cells, the majority is transported to the lysosomes through
the mannose-6-phosphate pathway (Sahagian and Gottesman,
1982). Within the acidic compartment, procathepsin Lis
processed to the single-chain mature form via cleavage
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between Lys 113 and Ile 114 (amino acid numbering starts
with Met-1 of the signal sequence). This form can be further
processed to the two chain species by cleavage between Ser290 and Asn-291. The large and small chains produced by this
final cleavage remain associated by disulfide linkage(s) in
the enzymatically active mature protein (Smith and Gottesman
1989; Ritonja et al., 1988).
Mature cathepsin L has been purified from a number of
eukaryotic origins, including human kidney (Ritonja et al.,
1988), rat (Towatari and Katunuma, 1988), rabbit (Mason and
Taylor, 1984), sheep (Mason, 1986), chicken (Dufour et al.,
1987) and human liver (Mason et al., 1985). In addition, the
precursor form of the enzyme has been isolated from the
cultured supernatant of transformed NIH/3T3 cells, which may
secret abundant amounts of the protein (Gottesman et al.,
1978) .

Enzymology of Cathepsin L

Mature cathepsin L isolated from the lysosomes
exhibits activity over a broad pH range, with maximal
activity between pH 4.5-5.5. The mature enzyme retains
activity, but is extremely unstable at neutral pH (Mason et
al., 1985; Kirschke 1982). In contrast, procathepsin L, the
secreted form of the protein, is very stable at neutral pH,
but has little or no protease activity in that range
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(neutral pH), which suggests that propeptide might be
involved in protein stabilization at neutral pH.
Mature cathepsin L is the most active lysosomal
protease in vitro against a variety of neutral substrates,
including aozcasein (Treen et al., 1987), elastin (Mason et
al., 1986) and collagen (Kirschke et al., 1982). No absolute
bond specificity of cathepsin L action has been determined,
though it may show a preference for peptide bonds near
hydrophobic amino acids (Mason et al., 1985).
Cathepsin L can be distinguished from other
cathepsins by its very limited activity in hydrolyzing some
synthetic substrates. Z-Phe-Arg-NMe has turned out to be the
most useful synthetic substrate for assaying cathepsin L
activity (Kirschke et al., 1982). It is extremely
susceptible to cathepsin L hydrolysis, but much less
sensitive to proteolysis by cathepsin B, with Km values
differing by as much as 20- to 50-fold for the two enzymes
(Mason et al., 1985; Mason et al., 1987; Kirschke et al.,
1982) .

Requlation of Expression of cathepsin L

There are several reports on the regulation of
cathepsin L synthesis by growth factors such as PDGF and EGF
(Scher et al.; 1983, Nielsen-Hamilton et al., 1982), tumor
promoters such as phorbol-myristate-acetate (PMA or TPA),
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protein kinase A - cAMP (Kane and Gotterman, 1990), and ras
oncogene transformation (Gottesman, 1979) which have been
shown to increase cathepsin L synthesis in mouse fibroblast
cells (Gottesman and Sobel, 1980). Increases of cathepsin L
have also been reported to be associated with activation of
macrophage (Portnoy et al., 1986), and on treatment of
bovine endothelial cells with heparin (Cochran et al.,
1988) .

cathepsin L and Tumor Malignancy

A cathepsin L-like protein was first reported as a
major excreted protein (MEP) whose extracellular and
intracellular abundance was augmented when mouse fibroblasts
were transformed by tumor viruses or methylcholanthrene
(Gottesman, 1978). In subsequent work the protein was
purified and shown to possess the lysosomal marker mannose6-phosphate (Sahagian and Gottesman, 1982). The sequence of
MEP cDNA was determined and its deduced amino acid sequence
was found to be identical to a partial protein sequence of
cathepsin L (Troen et al., 1987). MEP was found to be the
precursor to the lysosomal form of cathepsin L, i.e.
procathespin L. Malignant transformation by several
different oncogenes increases the rate of synthesis and
secretion of procathepsin L (Gottesman 1979). A set of
lOTl/2 cell lines that had been transfected by the T24-H-ras
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oncogene revealed a positive correlation between metastatic
potentials and MEP (Denhardt et al., 1987).

Cysteine Proteinase Inhibitors (CPI)

The cystatin superf amily of cysteine proteinase
inhibitors (CPI) consists of three families:

(1) the

stefins, (2) the cystatins and (3) the kininogenes. In terms
of inhibition of cathepsin B, the stefins and cystatins
appears to be more physiologically important as their Kis
for inhibition of cathepsin B are much lower than the
kininogenes (Barret, 1987).
The stef in family of CPis have been purified from
human liver (Lah et al., 1989) and a human sarcoma (Sloane
et al., 1989). They consist of proteins of about 11 kD that
have no disulfide bonds or carbohydrate and exist primarily
intracellularly. Two type of stefins have been identified:
stef ins A with acidic isoelectric points and stef ins B with
neutral isoelectric points.
The cystatin superf amily is another class of natural
proteins known to interact strongly with cysteine proteases
in vivo (Barrett, 1987). These are reversible, competitive
inhibitors. The cystatins may localize to the cell
cytoplasm, resulting in inactivating lysosomal proteases
that escape out of the lysosomes into other parts of the
cell. Many of the cystatins can also be secreted into the
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extracellular environment and are found circulating in
plasma. These inhibitors may serve as a further safeguard
against cysteine proteases which have leaked out of cells,
or they might be part of an intricate regulatory mechanism
of extracellular protease activity (Kruithof, 1983).
Down-regulation of the synthesis of stef in A occurs
during the progression of murine epidermal carcinomas from a
pre-malignant to a malignant state {Hawley-Nelson et al.,
1988). A reduced amount was found in skin tumors (Jarvinen
et al., 1987), and B16a tumors were found to have less
stefin A than normal liver cells {Sloane, 1990).
Analyzing the subcellular distribution of cathepsin
L suggests that CPI might be involved in regulating of
cathepsin L activity in murine B16 amelanotic melanoma cells
(Rozhin et al., 1989). The plasma membrane fractions from
B16 melanoma subpopulations of "low" and "high" metastatic
potential were assayed for activity of cathepsin L and for
heat stable endogenous cathepsin L inhibitors. The relative
specific activity of cathepsin L was 7-fold greater in the
subpopulation of "high" metastatic potentials, whereas
cysteine proteinase inhibitory activity was 5-fold less.

Tissue Inhibitor of Metalloproteinases (TIMP)

The TIMPs are stoichiometric inhibitors of many
mammalian metalloproteinases including collagenases that
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degrade interstitial collagens (type I-III) as well as type
IV and V collagens (Liotta et al., 1982; Goldfarb and
Liotta, 1986; Torgeirsson et al., 1982). The TIMP family
consists of at least two members. TIMP-1, first isolated
from rabbit bone, is a glycoprotein with a core polypeptide
of Mr 21,000 produced by many mesodermal tissues and is
found in a wide variety of human body fluids and cells in
culture (Welgus and Stricklin, 1983; Welgus et al., 1985).
Determination of the molecular weight of the secreted,
glycosylated protein ranged from 25,000 to 36,000 (Cawston,
1986; Drouin et al., 1988). The human TIMP-1 has been
isolated (Welgus et al., 1983), cloned and sequenced by
several groups (Carmichael et al., 1986; Docherty et al.,
1985; Gasson et al., 1985). Mouse cDNA (Edwards et al.,
1986), and rabbit (Horowitz et al., 1989). cDNA clones have
also been isolated. The encoded proteins of the murine and
human TIMPs are 76% identical at the nucleotide level and
73% identical at the amino acid level. Murine TIMP-1 has
been mapped to the X-chromosome (Jackson et al., 1987).
Human TIMP-1 is identical in amino acid sequence to a human
collagenase inhibitor isolated from human fibroblasts
(Carmichael et al., 1986) and also inhibits other neutral
metalloproteinases with gelatinase, proteoglycanase, and
stromelase activities (Heath et al., 1982; Sellers et al.,
1979) .
The expression of TIMP-1 mRNA in murine fibroblasts
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is induced by serum, platelet-derived growth factor,
epidermal growth factor, and PMA (Edwards et al., 1986;
Gewert et al., 1987; Denhart et al., 1986). A coordinated
temporal regulation of metalloproteinases and TIMP have been
observed in human fibroblasts which are induced to produce
TIMP, and to suppress collagenase and stromelysin, under
stimulation of transforming growth factor beta-1 (Machida et
al., 1988; Overall et al., 1989).
Natural TIMP-1 has been shown to inhibit tumor cell
invasion of the human amnion, which models invasion of tumor
cells across the basement membrane and stroma in vitro
(Torgeirsson et al., 1982; Mignatti et al., 1986). The most
direct evidence of metalloproteinase involvement in cancer
metastasis has came from this laboratory which showed that
human recombinant TIMP acts as an inhibitor of tumor cell
invasion in the in vitro amnion membrane invasion assay and
in an in vivo lung colonization assay with B16 FlO melanoma
cells in C57BL/6 mice (Schultz et al., 1988).
TIMP-2 is nonglycosylated and has recently been
isolated from media conditioned with human melanoma cells
(Stetler-Stevenson et al., 1989) or bovine endothelial cells
(De Clerck et al., 1989). TIMP-2 shares a 43% amino acid
sequence homology with the TIMP-1 and is found as a complex
with the 72-kD type IV procollagenase, an enzyme closely
linked to the invasive phenotype of both human melanoma and
endothelial cells (Goldberg et al., 1989).
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structure of Mammalian Ras

All the properties of both normal and malignant cells
are determined by the subset of those genes expressed in
their genome. A number of these genes have been shown to
have a role in the process of malignant transformation and
have been termed oncogenes. Oncogenes are derived from
normal genes (proto-oncogenes or cellular oncogenes) that
are highly conserved in evolution and that code for proteins
that have important roles in normal cellular processes such
as the regulation of gene expression or the transduction of
growth signals. Of the 50 to 60 oncogenes so far identified
as capable of transforming cells, the ras family of
oncogenes are among the most frequently activated in human
cancer (reviewed by Bos, 1989).
The ras genes include (at least) three wellcharacterized genes that have been associated with human
cancers: Harvey-ras (H-ras), Kirsten-ras (K-ras), and N-ras
(Barbacid, 1987; Bos, 1989). All of the three ras genes code
for closely related 21-kD proteins that can bind GDP and
GTP, and also have intrinsic GTPase activity which functions
to convert Ras-GTP to Ras-GDP. Rates of GTP hydrolysis by
wild-type Ras protein, but not oncogenic protein, are vastly
elevated in vivo (Trahey and MoCormick, 1987). The
discrepancies led to the discovery of GAP, a GTPaseactivating protein found ubiquitously in cell. The carboxy-
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terminal 40K acts catalytically upon wild-type Ras proteins
to stimulate their hydrolysis of bound GTP, but fails to
stimulate GTP hydrolysis by mutant oncogenic Ras (Marshall
et al., 1989). The ras proteins share structural homology
with G proteins and play a role in the transduction of
growth signals. The transforming potential of ras proteins
(p21) is usually associated with a point mutation in the
codons encoding amino acids 12, 13, or 61 (Sistonen and
Alitalo, 1986). These critical amino acid substitutions all
occur in or near the GTP binding domain of the protein, and
the transforming potential of altered p21 is associated with
the loss of GTPAse activity. This view has been recently
confirmed by crystallographic studies of the protein (Tong
et al., 1989)
Ras proteins are in the cytosol and become associated
with the inner side of the plasma membrane for functional
activity. Mutations at the cysteine of the COCH-terminal
Cys-a-a-X box (where a is an aliphatic amino acid and X any
of the common amino acids) generate an inactive cytoplasmic
protein by blocking a complex series of post-translational
modifications that includes removal of the three terminal
amino acids and polyisoprenylation of the new COCH-terminal
cysteine (Hancock et al., 1989). The Cys-a-a-X box is a
general signal for addition of the 15-carbon farnesyl lipid
moiety which increases the hydrophobicity of the protein,
but a further signal is required for targeting to specific
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membranes (Holtz et al., 1989). Localization of N-ras and Hras to the plasma membrane requires addition of palmitic

~

acid at another cysteine residue (181 or 184). In cellular
Ki-ras, which does not contain an upstream cysteine and is
not palmitoylated, a region rich in basic amino acids
(residue 175-182) seems to provide this additional signal
(Holtz et al., 1989).

Functions of Mammalian Ras

Genetic analysis of mammalian Ras is not yet possible
and biochemical approaches have been used to analyze its
function. Although the

~

genes cannot be deleted, the

proteins can be neutralized by microinjecting antibodies to
Ras into cells treated with growth factor (Mulcahy, 1985).
The result shows that the ras product is essential during
the first 8 hours of the G1 phase of the cell cycle. After
this time cells are committed to complete G1 , enter the

s

phase, and complete a cycle.
Although mutationally activated ras genes suffice to
transform NIH 3T3 mouse fibroblasts in vitro, a single
genetic event is probably not sufficient to cause human
cancers. In fact, it is believed that as many as five or six
steps are required for human malignancies (Weinberg, 1989).
The cooperation of ras genes with other oncogenes has been
elegantly shown in the now classic experiments of Land and
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coworkers (Land et al., 1983). Rat embryo fibroblasts (REF
cells) could be transformed only when at least two different
oncogenes were introduced: a myc-like and a ras-like gene.
so far, little progress in identifying the Ras
signaling pathway has been made from analyzing changes in
second messengers. It is not known whether Ras controls the
classical growth factor responses such as phospholipid
turnover and protein kinase activation or whether it
generates a novel signal.

structure and Function of Ras in yeast §. cerevisiae.

Saccharomyces cerevisiae contains two genes, RASl and
RAS2, which produce ras-like gene products. The RASl and
RAS2 proteins contain 309 and 322 amino acids, respectively,
compared to the mammalian p21 of Ha-ras protein with 189
amino acids. Alignment of the sequence of the mammalian p21
with RASl and RAS2 proteins show the yeast Ras contains
seven additional amino acids on the NH 2 -terminal end and the
rest of the additional amino acids (except for one) are
added to the COCH-terminal end of the p21-ras sequence. The
first 80 amino acids of mammalian Ha-ras show a greater than
90% identity to the near NH 2 -terminal sequences in the yeast
RAS proteins (residues 8 to 88), and the next 80 amino acids
show nearly 50% identity (Powers, et al., 1984).
Based on their extensive sequence and structural
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homology, yeast and mammalian Ras proteins show an apparent
functional homology. Mammalian ras can substitute for yeast
RAS genes

in~

cervisiae (Kataoka, et al., 1985). In turn,

mutated RASl can transform mammalian cells (Bradley, et al.,
1986) .
Genetic analysis has provided important insights into
the function of the ras proteins in this organism. Deletion
of both RASl and RAS2 genes, for example, is lethal, but
cells can be rescued by the gene (BCYl) encoding the
regulatory subunit of the cAMP-dependent protein kinase
(Toda et al., 1985). This RAS-deficient strain can be
stimulated in vitro by addition of recombinant Ras protein
of yeast or mammalian source (Broek et al., 1985). There is
no doubt that in S. cerevisiae Ras proteins regulate
adenylate cyclase activity and cAMP concentrations (Broek et
al., 1989). There is still some doubt, for example, whether
Ras activates adenylate cyclase directly or through an
intermediary cyclase-associated protein (CAP), and there is
strong genetic indication that Ras controls another
additional signaling pathway distinct from adenylate cyclase
but essential for cell viability (Field et al., 1990). The
proteins encoded by IRAl and IRA2 genes both have homology
to mammalian GTPase activating protein (GAP). Strains
deleted in IRAl can be rescued by introducing the mammalian
GAP gene (Tanaka et al., 1990). These finding suggest that
IRAl and IRA2 encode GAPs involved in the down-regulation of
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Ras.

Tumor Promoting Phorbol Esters

Tumor promoting phorbol esters were isolated from the
oil of the Euphorbiacea Croton tiglium L and structurally
identified to be a

diacylgly~erol

analog (Hecker 1968; van

ouuren et al., 1965). The most potent phorbol ester is
phorbol-12-myristate-13-acetate (abbreviated as PMA or TPA).
one of the best known effects of PMA is to enhance
transformation of cells to tumor cells (Blumberg et al.,
1988). PMA can induce normal cells into the tumor initiation
stage of carcinogenesis (Slaga, 1984).
In addition to its tumor promoter property, PMA has
been found to have a pleiotropic action on cells causing
alterations in the state of differentiation, proliferation,
metastatic potentials and the expression of specific genes
(O'Brian and Ward, 1989; Weinstein, 1988; Blumberg, 1988).
PMA binds to and directly activates the phospholipiddependent protein kinase C -(PKC), a major protein in the
inositol phosphate signal transduction pathway (Nishizuka,
1988; Person et al., 1988). The activation of PKC by PMA
mimics the action of the inositol phosphate generated
diacylglycerol on PKC (Castagna et al., 1982; Ashendel,
1985). Activated PKC binds to the plasma membrane and
through its catalytic phosphorylations on substrate
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effectors, which have not yet been identified, induces the
described pleiotropic changes (Kiss, 1990). A part of its
action is to increase the expression of the early response
oncogenes, c-fos, c-myc and c-jun (Abate and Curren, 1990).
The c-Fos protein and c-Jun protein form the AP-1 complex
which binds to the PMA or TPA response elements (TREs)
present in the phorbol ester responsive genes (Abate and
Curran, 1990; Chiu et al., 1988; Sassone-Corsi et al., 1988;
Lamph et al., 1988).
The mechanism of activation of PKC by phorbol ester
is still a open question. The protein kinase C (PKC) family
of phospholipid-dependent protein kinases play a key role in
signal transduction. The PKC isoenzymes are normally
activated by diacylglycerol (DAG), one of the products of
the receptor-mediated hydrolysis of inositol phospholipid,
and also by certain drugs, including the phorbol ester tumor
promoters. PKC isoenzymes consist of a catalytic (carboxylterminal half) and a regulatory domain (amino-terminal half)
(Nishizuka,1988). The catalytic domain contains sequences,
including an ATP-binding site, that resemble other protein
kinases. All PKC isoenzymes contain a so-called
pseudosubstrate motif and a tandem repeat of cysteine-rich
sequence in their regulatory domain (Nishizuka, 1988). The
central motif of the pseudosubstrate region (RKGALR) is
identical in sequence and position in PKC isoforms a, b and
rPKC (House and Kemp, 1987). It has been suggested that
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cysteine-rich regions in PKC are essential for phorbol-ester
binding (Ono et al., 1989). It is possible that the phorbol
ester as well as DAG are hydrogen-bonded to the sulfhydryl
groups in these cysteine-rich regions (Gechwendt, 1991).
PMA is known to induce the expression of genes coding
for collagenase (Whitham et al., 1986), stromelysin
(Matrisian et al., 1985), urokinase (Degen et al., 1985;
collart et al., 1986; Bell et al., 1990), cathepsin L
(Gottesman and Sobel, 1980) and metallothionein (Imbral and
Karin, 1987; Angel et al., 1987). These proteins may play a
role in invasion and metastasis (Mignatti et al., 1986).
Some products of proto-oncogenes, such as the products of
sis (Colamonici et al., 1986), myc (Greenber and Ziff, 1984;
Kelly et al., 1983), pro-1 (Lerman and Colburn, 1987), fos
(Kruijer et al., 1984), and

c-Ha-~

(Balmain et al., 1984;

Weinstein, 1987) are potential targets for PKC. The most
direct evidence for PKC involvement in tumor metastasis is
from an experiment that pre-treats B16 melanoma cell
sublines with PMA and shows promotion of the metastatic
potential of these treated cells in a lung colonization
assay (Gopalakrishna and Barsky, 1988).

CHAPTER I I I
MATERIALS AND METHODS

Materials

Zeta-probe filters were from Bio-Rad (Richmond,
CA.), a-32P-dCTP and a-32P-UTP (specific activity 3,000
ci/mmol) were from ICN Biomedicals, Inc.,

(Irvine, CA). NACS

PREPAC CARTRIDGE and the Nick Translation System were
purchased from BRL Life Technologies, Inc., Geithersburg,
MD. Kodak X-OMAT AR Diagnostic Film was from Eastman Kodak
Co.

(Rochester, NY). Intensifying screen (Dupont Cronex

Lighting Plus GJ 220004) was purchased from Dupont Co.
(Wilmington, DE). Polyclonal antibodies against human PAI-2
and goat anti-mouse antibody were purchased from American
Diagnostica Inc.,

(New York, NY). The BCA protein assay kit

was from Pierce Chemical Company, Rockford, Ill.
The cell culture supplies were purchased from either
Flow Laboratories (McLean, VA) or Gibco Laboratories (Grand
Island, NY).
The substrate for uPA enzymatic activity analysis,

s-

2251 (H-D-Val-Leu-Lys-p-nitroanilide) was purchased from
KabiVitrum, Stockholm, Sweden. The substrate for cathepsin L
32
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enzymatic activity analysis, N-carbobenzoxy-L-Phe-L-Arg-7aminomethylcoumarin (Z-Phe-Arg-AMC), was from BACHEM
Bioscience Inc. (Philadelphia, PA).
The mouse uPA cDNA plasmid was a gift of D. Belin
(University of Geneva), the mouse CL cDNA was a gift of L.
Joseph and V. P. Sukhatme (University of Chicago), the mouse
CB cDNA was a gift of s. J. Chan (University of Chicago),
human uPA cDNA was from W. E. Holmes, (Katholieke
Universitert Leuven, Belgium), human TIMP cDNA was a gift of
D. F. Carmicheal (Synergen Company, Colorado), human PAI-1
cDNA was from D. J. Loskutoff (Scrips Institute, La Jolla,
CA), and human PAI-2 cDNA was a gift from J. E. Sadler
(Washington University, st. Louis, MO.). Drosophila actin
was from Dr. Mark Kelly (Loyola University of Chicago), and
human glycerol aldehyde phosphate dehydrogenase cDNA
containing plasmid was obtained from American Tissue Culture
Collection.
Mouse cathepsin B (1,130 base pairs (bp)

(Chan,

1986), mouse uPA (1,000 bp) (Belin, 1985), mouse cathepsin L
(1,100 bp)

(Joseph et al., 1988), human uPA {880 bp) {Holmes

et al., 1985), human TIMP {800 bp) {Carmicheal et al.,
1988), PAI-1 {3,000 kb) {Loskutoff, 1985), human PAI-2
{l,800 bp) {Sadler, 1987) cDNA fragments were prepared in
this laboratories. Enzymes and chemicals were purchased from
Bethesda Research Laboratories {BRL, Geithersburg, MD) and
Boehringer Mannheim Biochemicals {Indianapolis, IN). All of
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these fragments were obtained by digesting the plasmids with
the endonuclease suggested by the providers, and the
resulting digested patterns are consistent with the
published literatures. The endonucleases utilized to
digested these plasmids to obtain the fragments for Northern
hybridization are discussed below, under Electrophoresis and
Northern Blot Analysis.

cell Lines

Non-transformed NIH 3T3 and NIH 3T3 murine
fibroblasts transfected with 4 different ras oncogene
constructs were obtained from M.

o.

Bradley (Merck Research

Institute, West Point, PA), and have been characterized with
respect to their metastatic potential in nude mice (Bradley,
et al., 1986). Their characteristics are shown on Table 1.
The PC3-P and PC3-M cell lines, which are human
prostate carcinoma cell lines, were obtained from Dr. James
Kozlowski (Northwestern University, Chicago, Ill.). The PC3M cells are highly metastatic in the nude mice, while the
PC3-P (parental) cells have a significantly lower metastatic
potential (Kozlowski, et al., 1984).
A375-P & A375-M cells lines, derived from a human
melanoma, were kindly provided by Dr. I.J. Fidler
(University of Texas, M. D. Anderson Medical Center,
Houston, TX). A375-P cells show a low metastatic potential
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in nude mice and A375-M is a high metastatic derivative
(Kozlowski et al., 1984). A summary of major properties of
above two cell lines are in Table 2.
The PC3-P and M cells were grown in Eagle's minimal
RPIM 1640 supplemented with 10% heat-inactivated fetal
bovine serum (HI-FBS) (Flow Laboratory, McLean, VA) and 100
units/ml of penicillin and 100 ug/ml of streptomycin sulfate
(Gibco Laboratories) •
The A375-P and SM cells were grown in Eagle minimal
essential medium (MEM) supplemented with 10% heatinactivated fetal bovine serum (HI-FBS)

(Flow Laboratory,

McLean, VA), 1% MEM nonessential amino acids (Gibco
Laboratories, Grand Island, NY), 1 mM sodium pyruvate, 1 mM
MEM vitamin solution, 100 units/ml of penicillin and 100
ug/ml of streptomycin sulfate (Gibco Laboratories).
For the subculture of these human cells, the cells
were detached from the cell culture flask by using 1 mM of
ethylenediamine tetracetic acid (EDTA) in phosphate buffer
saline (EDTA-PBS), pH 7.4, and were split 1:5.
All cell lines discussed above were incubated at 37°C
in 5% C0 2 saturated with water vapor and maintained by
changing the medium every 2-3 days. The total number of
passages was less than 3 to keep the genetic drift of the
cells to minimal levels.
Medium and supplements used in these cell cultures
are summarized in Table 3.

Table 1

Characteristics of ras Oncogenes Transf ected
NIH 3T3 Fibroblasts
(Data from Bradley et al., 1986)
8

CELL LINE

ONCOGENE CONSTRUCT

Ras MUTATION

NIH/3T3

Ras Proto-oncogene

Gly

12

EJ-ras

Human Bladder Carcinoma T-24

Val

12

EJ/vHA-ras

Chimeric Human
and Viral-oncogene

Val

12

HYB CLeu

Chimeric Yeast
and Viral-oncogene

Gly , Ala , Leu ,

Recombinant Yeast
Oncogene

Gly , Ala , Leu ,

,

Ala

59

,

Ala

59

,

Thr

59

Average No. of
tumor per lung

,

Gln

61

,

Gln

61

,

Gln

61

19

66

68

19

66

68

S.D.

,

0

0

,

9

14

,

72

32

40

>280°

29

8underlined amino acid represents a mutation from normal amino acid of cellular Ras protein
at designated position 12, 59 or 61. In yeast sequence position 19, 66 and 68 are equivalent
to 12, 59, 61 of mammalian Ras.
bNumber of injected cells was 2.9 x 10
0

Number of injected cells was 1.8 x 10

5

5

per mice.
per mice.

w
O'I

TABLE 2 Experimental Metastasis of Human Tumor Cells
in Nude Mouse
(Data from Kozlowski et al., 1984}
median no. of
apparent lNng tumor
nodules

no. of animals with
metastases
in lung

microsco~c

Cell Line

origin

A375-P

Human Melenoma

0 {0-5}c

2/5

A375-M

Human Melenoma

69 (0-250)

5/5

PC3-P

Human Prostate
Carcinoma

0

PC3-M

Human Prostate
Carcinoma

38 (0-250)

1/15
13/15

aNumberof grossly apparent tumor foci on lung surface were determined with the aid of a
dissecting microscope.
bstepwise sections from lungs of each animal were examined for present of microscopic
parenchymal metastases.
cNumber in parentheses, range.
w
-....]
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TABLE 3 Culture Medium of Cell Lines

Name

Species Medium

supplement

Detachment media

-----------------------------------------------------------mouse
DMEM
0.1% trysin &
10% HI-FBS
8

NIH/3T3

gentomycin

1 mM EDTA

EJ-ras

mouse

DMEM

10% HI-FBS
gentomycin

0.1% trysin in
1 mM EDTA

EJ/vHa-ras

mouse

DMEM

10% HI-FBS
gentomycin

0.1% trysin &
1 mM EDTA

HYB C

mouse

DMEM

10% HI-FBS
gentomycin

0.1% trysin &
1 mM EDTA

mouse

DMEM

10% HI-FBS
gentomycin

0.1% trysin &
1 mM EDTA

human

RMPI 1640 10% HI-FBS
b

1 mM EDTA

RMPI 1640 10% HI-FBS

1 mM EDTA

PC3-P

S. P.

PC3-M
A375-P

human
human

s.

MEM

p.

10% HI-FBS

1 mM EDTA

S. P.

A375-SM

human

MEM

10%-HI-FBS

1 mM EDTA

S. P.
8

HI-FBS: heat-inactivated fetal bovine serum.

bS.P.: streptomycin 100 ug/ml and pencillin 100 units/ml.
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Preparation of mRNA

Northern blots were used to study the correlation
between steady-state mRNA levels of the genes and metastatic
potentials. The procedure for preparation of glasswares and
the solutions were ones described by Maniatis (1984). The
cultured cells were washed with cold phosphate-buffer saline
(PBS), removed from the flasks with 1 mM EDTA-PBS and
pelleted by centrifugation. The pellet was resuspended with
1 ml of 10 mM Tris (pH 7.9), 1.5 mM MgC1 2 , and 0.15 M NaCl.
The suspension was mixed with 200 ul of detergent solution
containing 10 mM Tris, 1.5 mM MgC1 2 , 1.5 mM MgC1 2 ,

0.15 M

NaCl and 13% NP-40, and kept in ice for 10 min. The nuclei
were pelleted at 10,000 rpm, the supernatant was poured into
a 30 ml Corex tube with 1 ml of buffer (10 mM Tris, 0.35 M
NaCl, 5 mM EDTA, 1% sos and 7 M urea), 2 ml phenol and 6 ml
chloroform. The pellet was saved at -70°C for later nuclear
transcription assays. The initial supernatant was
centrifuged again and the upper liquid portion was
transferred to a clean tube. After the addition of 2.5
volumes of cold ethanol, the tube kept at -20°c overnight.
The RNA precipitate was obtained by centrifuging at 10,000
rpm for 20 min. The concentration of RNA was determined with
a UV spectrophotometer at 260 nm (Maniatis, 1982).
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Electrophoresis and Northern Blot Analysis

The poly(A) rich RNA was obtained using poly(dT)
resin chromatography (BRL). The resulting RNAs were
separated overnight by electrophoresis in 1% agarose, 0.02%
formaldehyde gel in MOPS buffer (0.2 M MOPS, 0.05 M sodium
acetate, 0.01 M EDTA) at 25

v.

The RNAs were transferred to

zeta-probe Membrane (Bio-Rad, CA) by the capillary transfer
method in 20 x SSC (lx SSC = 0.15 M NaCl, 0.015 M sodium
citrate, pH 7.0) overnight and immobilized by the UV
crosslinking technique (UV Stratalinker 1800, stratagene, La
Jolla, CA). For preparation of the respective cDNA probes,
the mouse uPA cDNA containing plasmid was double digested
with Hind III/EcoRl; the mouse cathepsin B plasmid was
double digested with Hind III/EcoRl; the mouse cathepsin L
plasmid with BamHl, the human TIMP plasmid with EcoRl; human
PAI-1 plasmid with EcoRl; human PAI-2 plasmid with EcoRl.
The DNA fragments were separated in 1% low-melting agarose
(Sigma Chemicals Co.) by electrophoresis and the fragments
of interest were identified by their expected molecular
weight, and isolated from the gel by razor blade.
The fragments were labeled with

32

-P-dCTP by a random-

primer labeling kit (Boehringer Mannheim Biochemicals).
Briefly, DNA fragments were first denatured by heating for
10 min at 95°C and subsequently cooling on ice. The DNA
hexanucleotide mixture, 2 U Klenow enzyme and 50 uci of 32-
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p-dCTP were mixed with a buffer solution containing 0.25

mM

dATP, dGTP, dTTP, the reaction carried on in 37°C for 1 hr,
and unincorporated

32

-P-dCTP separated with a NACS Prepac

cartridge (BRL) .
Sometimes labeling was carried out by the nick
translation procedure (Nick Translation System, BRL Life
Technologies, Inc., Geithersburg, MD). The plasmid DNA was
added to the reaction mixture containing dATP, dGTP, dTTP,
and

32

-P-dCTP (ICN Biomedicals, Inc., Irvine, CA) and nick-

translated by incubation with 1 U of DNA polymerase I and
100 pg of DNase I at 15°C for 60 min.
The labeled DNA fragments were hybridized in to the
filter bound in RNAs in a hybridization solution containing
0.5 M NaH 2 P0 4 pH 7.2, 0.25 M EDTA and 1% bovine serum
albumin at 65°C overnight. The filter was washed 2 times for
30 min each with 10

mM

EDTA, 40

mM

NaH 2 P0 4 ,

0.5% bovine

serum albumin fragment V (Boehringer Mannheim Biochemicals)
and 1%
mM

sos;

and two times for 30 min each with 10

mM

EDTA,40

NaH 2 P0 4 , 1% SOS. The filter was exposed to X-ray film

(Kodak X-OMAT AR Diagnostic Film, Eastman Kodak Co.,
Rochester, NY) at -70°C with an intensifying screen (Dupont
Cronex Lighting Plus GJ 220004, Dupont co., Wilmington, DE).
To estimate the relative amounts of hybridization, the
autoradiograms were scanned with a Beckman Densitometry
System or other similar densitometer. For rehybridization,
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the attached probe was removed by washing the filter at 95°C
2 times for 20 min each in 0.1 x SSC containing 0.5%

sos.

The filter was exposed to X-ray film to check the efficiency
of the stripping. The stripped filter was then rehybridized
as described above.
For the internal standard control, the filter was
similarly hybridized with either

32

P-labeled plasmids

containing the Drosophila actin cDNA (Fryberg et al., 1983)
obtained from Dr. Mark Kelly (Loyola University Medical
center) or a human glyceraldehyde-3-phosphate dehydrogenase
(GAPD)

(American Tissue Culture Collection), and the labeled

filter exposed to X-ray film.

Time Course of Stimulation of Protease and AntiProtease Genes by Phorbol Ester

Phorbol ester stimulation of gene expressions of
proteases and protease inhibitors were assayed by the slot
and Northern blot techniques. In these procedures the cells
were grown in T-75 culture flasks (GIBCO, Grand Island, NY)
until subconfluent. The culture medium was then removed and
10 ml fresh medium with 10% heat-inactivated fetal bovine
serum (HI-FBS) and 20 nM phorbol-12-myristate-13-acetate
(PMA, Sigma Chemical Co.) was added. After incubation with
PMA for 2, 4, 8, 16, and 32 hr, the cells were harvested in
phosphate buffer saline containing 1 mM EDTA (PBS-EDTA) and
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centrifuged at 500 x g. The cells without PMA treatment,
designated

o

hr, was used as the unstimulated control. The

cytoplasmic RNA was extracted (see above). A Zeta-probe
filter was soaked in deioned water for 30 min, and the
filter was placed in a slot blot apparatus (Bio-Rad). RNAs
were denatured by incubating in a solution containing 45%
formamide, 0.01 M MOPS {Sigma Chemical Co.), 0.05 M sodium
acetate, 10 mM EDTA, 20% formaldehyde, 7.5% glycerol at 95°C
for 10 min. The filter was then rinsed in a solution
containing 10 mM NaOH and 1 mM EDTA, and hybridized with
32

P-labeled probes by the procedure described previously.

Northern blots were performed with RNA samples at a given
time points to verify the observations based on slot blots.

Run-on Assay for Transcription Rate

Increases in mRNA steady-state concentration may be
due to either an increased rate of synthesis or to a
decreased rate of degradation. In order to determine the
mechanism for the changes in mRNA levels observed in slot
blot procedure, run-on assays were carried out.
The procedure was as described by Nevins, 1987.
Nuclei, prepared as previously described in the section on
preparation of mRNA above, were washed in the reaction
buffer {20 mM Tris, pH 7.9; 20% glycerol; 140 mM KCl; 10 mM
MgC1 2 ; 1 mM dithiothreitol; 1 mM each ATP, CTP, GTP). The
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nuclei were quickly frozen in liquid nitrogen and stored at
-10°c in a freezer.

Nuclei were resuspended in reaction buff er containing
32

nucleotide triphosphates, alpha- P-UTP {ICN Biomedicals,
Inc., Irvine, CA) and creatine kinase (BRL, Geithersburg,
MD). The nuclei were incubated at 37°C for 10 min. The
reaction was stopped by the addition of a 1 ml solution
containing 10 mM Tris {pH 7.4), 0.5 M NaC1 2 , 50 mM MgC1 2 and
2 mM CaC1 2 to lyse the nuclei. The unincorporated label was
removed by a 3 times repeated ethanol precipitation of the
labeled product. Labeled RNA was dissolved in 200 ul of 0.02
M Tris-HCl {pH 7.4), 1 mM MgC1 2 and incubated with 50 ug/ml
DNase {Sigma Chemical Co.) at 37°C for 15 min. DNase was
removed by extraction with phenol-chloroform. The RNA
product was fragmented by incubating with 0.2 N NaOH on ice
for 30 min, and an aliquot was removed for measuring
incorporated radioactivities with a Beckman LS 7500 Liquid
Scitilation System.
The plasmids containing the cDNAS for the genes of
interest were denatured by boiling the DNA in 0.1 N NaOH for
10 min. A nitrocellulose filter (Bio-Rad) was washed with 6
x SSC {l X SSC

=

0.15 M sodium acetate, 0.15 M sodium

chloride). The denatured cDNA-containing plasmids were
slowly loaded onto the filter. The filter was washed with 6
x SSC, dried, and baked in a vacuum oven at 80°C for 2 hr.
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The dried filter was first incubated in
prehybridization buffer containing 50 mM HEPES (pH 7.4), 0.3
M NaCl, 10 mM EDTA, 0.2% SOS, 1 mg/ml yeast tRNA (Boehringer
Mannheim Biochemicals, Indianapolis, IN), 0.5 mg/ml poly(A),
1% sodium pyrophosphate, 5 x Denhards't solution ion (1 x
oenharht 'solution equal 0.02 % polyvinylpyrilidone, 0.02%
bovine serum albumin, 0.02% Ficoll 400 and 0.02% BSA)
without albumin for 60 hr and replaced with hybridization
buffer containing 50 mM HEPES (pH 7.4), 0.3 M NaCl, 10 mM
EDTA, 0.2%

sos,

100 ug/ml yeast tRNA, 100 ug/ml poly(A),

o.1% sodium pyrophosphate, 1 x Denhardt's solution and equal
counts of the labeled RNA. The filter was incubated at 65°C
for 36-40 hr, washed 3 times with 2 x SSC at 65°C for 30
min, and treated with a mixture of Tl RNase (5 U/ml,
Borhringer Mannheim Biochemicals) and pancreatic RNase (2.5
ug/ml, Sigma Chemical Co.) in 2 x SSC for 1 hr at 37°C.
After digestion, the fluid was removed, and the filter was
washed 2 times with 2 x SSC at room temperature for 30 min.
The filter was then exposed to X-ray film (Kodak X-OMAT AR
Diagnostica Film, Eastman Kodak Co., Rochester, NY) at -70°C
with an intensifying screen (Dupont Cronex Light Plus GH
220004, Dupont Co., Wilmington DE).

Enzyme Assays for cathepsin L

1

NIH/3T3 fibroblasts, EJ/vHa-ras and RAS1 eudel-
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transformed NIH/3T3 fibroblasts were cultured 50,000
cells/well in 24-well flasks (Flow Laboratories). The cells
were grown in Dulbecco•s modified Eagle's minimal essential
media (DMEM) with 10% heat-inactivated FBS and 50 ug/ml
Gentamicin until subconfluent (80-90%), washed with PBS and
incubated in serum-free media for 24 h, the media collected,
and centrifuged at 10,000 rpm in Beckman Microfuge E.
The cells remaining in the wells were lifted with 1
mM EDTA in PBS and counted in a model ZBI Coulter counter,

the cells lysed with 1%

sos

and 1 mM EDTA in PBS, and

dialyzed against PBS for overnight in the cold room with 3
times changes. The resulting preparation were saved in -20
0

c.

The substrate N-carbobenzoxy-L-Phe-L-Arg-7-

aminomethylcoumarin (Z-Phe-Arg-AMC)

(BACHEM Bioscience Inc.

Philadelphia, PA) was used to assay for cathepsin L (Mason,
1986; Baricos, et al., 1988). Both cathepsin Band L can
catalyze the hydrolysis of this substrate. Based on the kcat
and

Km already reported for these substrates with the two

enzymes from human and rat (Mason, 1986; Baricos, et al.,
1988) at the substrate concentration of 5 uM, the cathepsin
L/cathepsin B activity ratio for Z-Phe-Arg-AMC was
calculated to be 9 to 1. Procathepsin L in the cells was
activated by pepsin (3900 units/mg protein, Sigma). The
optimal concentration of pepsin for activation of
procathepsin L was 1-2.5 mg/ml, which was determined
experimentally by varying the pepsin concentration stock
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solution (between O and 10 mg/ml in 0.2 M sodium acetate, pH
4 .2) in activation buffer (30 mM dithiothreitol and 15 mM
EDTA, pH 5.2) for 30 min at 37°C. The activity of the
activated enzyme was measured by the addition of 0.8 ml of
0.2 M Na citrate/Na phosphate at pH 6.2 containing Z-PheArg-AMC at final concentration of 5 uM .• The appearance of
product 7-aminomethylcoumarin (AMC) was followed in a SLMAminco SPF-500 c spectrof luorometer at room temperature at
excitation and emission wavelengths of 370 and 450 nm,
respectively.

Enzyme Assay for uPA

Urokinase plasminogen activator activity was measured
spectroscopically using a chromogenic substrate for plasmin
as previously described by Whur et al., 1980. The
plasminogen was pre-treated with diisopropylf luorophosphate
(DFP), to inhibit any active plasmin activity present.
Specifically, plasminogen was incubated with 25 mM DFP in 50
mM Tris buffer, pH 8.1, at 37°C for 1 hour, and then
extensively dialyzing against the same buffer. Plasmin
activity was measured in the DFP-treated plasminogen to
ensure endogenous activity was undetected by the assay.
Fifty ul of the medium was added to 100 ul of 100 mM
Tris buffer, pH 8.1, containing 5 ug of DFP-treated
plasminogen (Sigma Chemical Co.), 15 ug of S-2251 (H-D-Val-
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Leu-Lys-p-nitroanilide, KabiVitrum, Stockholm, Sweden), and
o.1% Triton X-100. After incubating for 16 hr at 37°C, the
concentration of p-nitroaniline, corresponding to substrate
hydrolysis by plasmin, was read at 405 nm in a Perkin-Elmer
320 spectrometer.
The background activity was determined by
substracting reaction buffer for conditioned medium, and
each subtrasting the background from each reading. Each
experiment was performed in three separate wells.
Plasminogen activator activity was expressed in absorbance
per 10 6 cells per hour.

Antisense Oligodeoxynucleotides Transf ection

The mouse urokinase gene (Degen et al., 1987) and the
mouse cathepsin L cDNA (Troen et al., 1988) have been
sequenced. The three 21-mer oligonucleotides sense-uPA (5'ATGAAAGTCTGGCTGGCGAGC-3 1), anti-uPA (5'GCTCGCCAGCCAGACTTTCAT-31), anti-CL (5 1CAAAAGGAGTAAAAGATTCAT-3 1) were made. The anti-uPA and antiCL sequences were in an antisense directions, respectively,
against the first 21 nucleotides starting from the 5 1 start
of translation in the mRNAs for uPA and CL, respectively.
The sense-uPA was made in the sense direction from the start
of translation of the uPA mRNA and was used as a control
oligo. In initial experiments NIH/3T3, EJ-vHa-ras- and
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RASlLeudel-transformed cells were seeded 50,000 cells per

=-------

well in a 24 well Petri dish (Flow Lab) and incubated for 24
hr in media containing 10% heated-inactivated FBS (HI-FBS).
The medium was changed to media containing an
oligonucleotide and incubated for 24 h. Anti-CL and anti-uPA
were used at concentration of 10 uM, 50 uM, 100 uM and 200
uM, 0.3 ml/per well. The wells were washed 3 x with serumfree media, 0.5 ml of serum-free media added to each well
and conditioned media removed every 12 hr, up to for 48 hr.
The conditioned media was centrifuged at 10,000 rpm
(Beckman) in 1.5 ml microcentrifuge tubes and saved at -20
0

c until assayed.

Lung Colonization Assay

The murine lung colonization assay was performed in a
similar manner as previously described (Bradley et al.,
1986). The semiconfluent cells were harvested by adding 0.1%
trypsin and 1 mM EDTA in PBS and the cells were quickly
removed from trypsin in complete medium, centrifuged at 500
x g, and resuspended in PBS (no calcium or magnesium). Cells
were counted in a Coulter counter, and diluted to 1,500,000
cells/ml. Cells were maintained on ice prior to injection.
Athymic female nude mice (Ncr nu/nu) were obtained from NIHFrederick Facility and housed in the Loyola Medical Center
Animal Care Facility in sterile cages for 1 week prior to
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use. The mice used in the experiment were 4-5 weeks of age
at the time of injection. A 0.2-ml cell suspension (300,000
cells/mouse) was slowly injected into the lateral tail vein
with a 26-gauge needle. The injection schedule was
alternated between animals in the control group and animals
in the experimental group, to minimize experimental
variances, especially time. At end of injection, cell
viability was determined by the trypan blue dye exclusion
test (Phillips, 1973) assay. Viable cells ranged 91-97%
under the experimental conditions.
The mice were maintained under sterile barrier
conditions and sacrificed 14 days after tail vein injection,
the lungs were removed, and the animal were examined for
disseminated tumor colonies. Lungs were fixed in Bouin's
solution and the number of surf ace colonies were counted
under a dissecting microscope.

Polyacrylamide Gel Electrophoresis

Discontinuous sodium dodecyl sulfate polyacrylamide
gel electrophoresis was performed to verify the induced
proteins in Western blots after phorbol ester stimulation of
the cell lines. The procedure was that of Laemmli (1970) as
detailed by Davis et al.

(1986). All electrophoresis

equipment and reagents were from Bio-Rad (Richmond, CA).
Gels were 16 X 18 X 0.75 cm thick and are composed of a
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stacking gel (4-5 cm) of 3% acrylamide and a resolving gel
of 11% acrylamide. Electrophoresis was performed at 10 mA
for overnight in a running buffer of 0.025 M Tris, 0.192 M
glycine (pH 8.3) containing 1%

sos.

The lower gel buffer was

o.5 M Tris pH 6.3 containing 1.5 M Tris (pH 8.8) and 0.4%

sos.

The stacking gel buffer was 0.5 M Tris, pH 6.3,

containing 0.4%

sos.

Samples for electrophoresis were

diluted 1:1 in sample buffer (10 ml glycerol, 23 ml of 10%

sos,

2 ml of 1% bromphenol blue, 8.3 ml stacking gel buffer

and 6.7 ml H2 0).

Western Blot

Western blot analysis was used to detect increased
amount of protein after phorbol ester stimulation.
Polyclonal antibodies against human PAI-2 and urokinase were
purchased from American Oiagnostica Inc.

(New York, NY). The

cells were grown in 6-well cell culture cluster dish (GIBCO,
Grand Island, NY) to subconfluence. Culture media (1 ml)
containing 20 nM PMA and 10% HI-FBS were added into the
flasks. The media were collected and the attached cells were
lysed with 0.2 ml of solution containing 1%

sos

and 1 mM

EOTA. The lysed cells were mixed with the collected culture
media and saved at -20°C until assayed. The protein
concentrations were determined by the BCA protein assay
method (Pierce Chemical Company, Rockford, Ill.). The
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procedure for SDS-polyacrylamide gel electrophoresis was the
same as that described as above. Ten mg of the protein
sample were loaded into each well. After electrophoresis,
the protein were transferred to a nitrocellulose filter
(Bio-Rad, Richmond, CA) with an electrophoretic transfer
apparatus (Bio-Rad) in a transfer buffer containing 0.05 M
Tris, 0.2 M NaCl, 0.05% Tween and 1% bovine serum albumin
(TBST buffer) for overnight at 4°C to block any non-specific
binding sites, washed for 30 min with TBST twice, and then
incubated with mouse anti-human antibody (American
Diagnostica Inc. New York, NY) at a concentration of 5 ug/ml
for 2 hr. Nonspecifically bound antibody was removed by
washing the filter with TBS 3 times. Biotinylated goat antimouse IgG (BRL) was next added at a concentration of 1.5
ug/ml in TBST. Bound antibody was detected with avidin
conjugated to horse-radish peroxidase (Avidin-HRP) and
BCIP/NBT (5-bromo-4-chloro-3-indoylphosphate/nitroblue
tetrazolium) as the substrate in carbonate buffer (0.1 N
NaHC0 3 , 10 mM MgC1 2 , pH 9.8) was added for color
development.

Preparation of Cultured Media from organ Fragments of
Nude Mice

The procedure for the collection of conditioned media
from organ culture was the similar to that described by
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(Price et al., 1988). Female bale mice (5-6 weeks) were
purchased from NCI-Frederick Facility and housed in the
Loyola Medical Center Animal Care Facility in sterile cages
for 1 week prior to use. The mice were sacrificed by
exposure to ether, and their lungs, kidneys and spleens were
detached. The organs were rinsed with the medium, and fatty
tissue was removed. The organs were cut with a razor blade
into 1-2 mm

3

pieces, washed 3 times with cold RMPI 1640

culture medium, and the pieces were incubated in cell
culture dishes with 10 ml of RMPI 1640 at 37

c

with 1% fetal

bovine serum for 6 hours, and replaced with 10 ml of fresh
media containing 10 % HI-FBS (Flow Lab). The media were
collected after 24 hr, and centrifuged at 500 x g to remove
debris.

CHAPTER IV RESULTS

1 • Expression of Mouse Urokinase mRNA in NIH 3T3 Fibroblasts

and ras oncogene Transformed NIH 3T3 Cell Lines with
Phorbol Ester (PMA) Treatment.

The NIH 3T3 cell lines transformed by the oncogenes
Leu
Leu
EJ-ras, EJ/vHA-ras, HYB c
and RASl del have been
previously described (Bradley et al., 1986). EJ-ras contains
an activating Gly to Val mutation at codon 12 and was
originally isolated from a human carcinoma (Capon et al.,
1983). The EJ/vHA-ras is a chimeric construct (Gibbs et al.,
1984), which combines the first 22 amino acid codons of
EJ-ras and the remaining COOH-end amino acids from the viral
v-Ha-ras gene. EJ/vHA-ras has two activating mutations, at
Leu
Leu
codons 12 and 59. HYB C
and RASl del are two yeast RASl
containing sequences used to transform the NIH 3T3 cells
(Defoe-Jones et al., 1985). The HYB CLeu gene contains the
yeast RASl sequences 1 to 161 joined to amino acids 154 to
189 from the v-Ha-ras sequence with residue 68 mutated to
Leu. Amino acid 68 is structurally analogous to amino acid
61 in the mammalian Ha-ras protein sequence (Table 4). The
RASlLeudel contains all yeast RASl sequences and was prepared
54
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by deleting amino acid codons 186 through 302 of RASl and
then ligating to codon 186 the COCH-terminal codons for
residues 303 to 309 in the RASl sequence which provide the
cys-a-a-X sequence required for farnesylation and membrane
association (Hancock, et al., 1989). The sequence also
contains the activating Leu mutation at amino acid position
68 (analogous to position 61 in the Ha-ras protein sequence,
Table 4). These activated mammalian ras and yeast RAS genes
transform NIH 3T3 fibroblasts into cells which are
tumorigenic and metastatic in nude mice (Bradley et al.,
1986) • The ras-transformed cells do not show a correlation
of metastatic ability with the amount of activated Ras
protein present (Bradley et al., 1986). Of the Ras
transformed cells, the EJ/vHa-ras and the RASl

Leu

del

transformations appear most malignant, each giving a 9- to
10-f old greater number of lung colonies than the other
Leu

activated Ras transformed cell lines (EJ-ras and HYB C -ras
) when tail vein injected into nude mice (Bradley et al.,
1986). The prior results of Bradley on the nude mice assay
of these ras-transformed cells are summarized in Table 1.
To study the correlation between mouse urokinase
expression and tumor metastatic potentials, the RNAs were
isolated from untransformed NIH 3T3 fibroblast and the four
different ras oncogene transformed mouse cell lines, under
subconfluent conditions. A slot blot analysis was carried
out to study relative amount of uPA mRNA among these cell
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lines. The results are shown on Figure 1. The highly
malignant EJ/vHa-ras-transformed cells show a high
constitutive level of uPA mRNA over NIH 3T3 controls and
other ras oncogene-transformed cells, (see zero hour time
point in Figure 1). However, the highly malignant
RAS1 10udel-transformed cells show low levels of uPA mRNA,
similar to control NIH 3T3 cells.
Tumor cells may change phenotype in the different
steps of metastasis. The change, if it occurs, may be
related to environmental signal factors near each of the
step barriers. A highly metastatic tumor cell in this
paradigm, is characterized by its facile ability to change
its phenotype in response to environmental signal factors.
As it is currently impossible to study how the protease
activities are actually regulated in vivo by signal factors,
I tried to obtain support for this idea by adding a tumor
promoter, the phorbol ester, phorbol-12-myristate-13-acetate
(PMA or TPA), into cell culture. While phorbol ester is not
a naturally occurring signal factor, it activates protein
kinase C (PKC) which is a part of the inositol phosphate
signal transduction pathway (O'Brian and Ward, 1988;
Weinstein, 1988; Blumer, 1988). This is one of the major
pathways by which extracellular signals are transmitted
intracellularly, and thus may mimic natural signals that a
tumor cell could encounter in the metastatic process.
Figure 1 then also shows the changes in steady-state

Table 4.
Jb

{EJ-ras}
{EJ/vHa-ras}
{c-Ha-ras}
{Hyb C}
{RASl-del}

.....•• MTE
....... MTE
.•..••. MTE
MQGNKSTirE
MSGNKSTirE

Alignment of Ras Sequencesa

*d
YKLVVVGAvG
YKLVVVGAvG
YKLVVVGAGG
YKiVVVGgGG
YKiVVVGgGG

VGKSALTIQL
VGKSALTIQL
VGKSALTIQL
VGKSALTIQF
VGKSALTIQF

IQNHFVDEYD
IQNHFVDEYD
IQNHFVDEYD
IQsyFVDEYD
IQsyFVDEYD

43
PTIEDSYRKQ
PTIEDSYRKQ
PTIEDSYRKQ
PTIEDSYRKQ
PTIEDSYRKQ
50

1

{EJ-ras}
{EJ/vHa-ras}
{c-Ha-ll§}
{Hyb C}
{RASl-del}

44
VVIDGETCLL
VVIDGETCLL
VVIDGETCLL
VVIDdkvsiL
VVIDdkvsiL
51

* *
DILDTAGQEE
DILDTtGQEE
DILDTAGQEE
DILDTAGLEE
DILDTAGLEE

YSAMRDQYMR
YSAMRDQYMR
YSAMRDQYMR
YSAMREQYMR
YSAMREQYMR

TGEGFLCVFA
TGEGFLCVFA
TGEGFLCVFA
TGEGFLlVYs
TGEGFLlVYs

93
INNTKSFEDI
INNTKSFEDI
INNTKSFEDI
VtsrnSFDEl
VtsrnSFDEl
100

{EJ-ras}
{EJ/vHa-ras}
{c-Ha-ras}
{Hyb C}
{RASl-del}

94
HQYREQIKRV
HQYREQIKRV
HQYREQIKRV
lsYyqQiqRV
lsYyqQiqRV
101

KDSDDVPMVL
KDSDDVPMVL
KDSDDVPMVL
KDSDyIPvVv
KDSDyIPvVv

VGNKCDLA.A
VGNKCDLA.A
VGNKCDLA.A
VGNKlDLeNe
VGNKlDLeNe

RTVESRQAQD
RTVESRQAQD
RTVESRQAQD
RqVsyedglr
RqVsyedglr

142
LARSYGIPYI
LARSYGIPYI
LARSYGIPYI
LAkqlnaPFl
LAkqlnaPFl
150

{EJ-ras}
{EJ/vHa-ras}
{c-Ha-ras}
{Hyb C}
{RASl-del}

143
ETSAKTRQGV
ETSAKTRQGV
ETSAKTRQGV
ETSAKqainV
ETSAKqainV
151

EDAFYTLVRE
EDAFYTLVRE
EDAFYTLVRE
DDAFYTLVRE
DEAFYsLIRl

IRQH •• KLRK
IRQH •• KLRK
IRQH •• KLRK
IRQH .• KLRK
VRddggKyns

LNPPDESGPG
LNPPDESGPG
LNPPDESGPG
LNPPDESGPG
MNrqlDgGcQ

189
CMSCKgVLS*
CMSCKgVLS*
CMSCKgVLS*
CMSCKgVLS*
iic* .•.•.•
193

--------------------------------------------------------------------------Ul
-....]

aAlignmentmade by the PILEUP alogrithms in Genetics Computer Group Software
[Devereux, J., Haeberli, P., Smithies,

o.

(1984) Nucleic Acids Research 12, 387-

395], using default settings. Upper case letters show consensus between three or more
sequences.

Sequences utilized from the GenBank and EMBL data bases are

human

c-Ha-ras-1 [accession number J00277] for c-Ha-ras, murine Sarcoma virus
{Harvey-strain) H-ras gene [accession number X00740] for v-Ha-ras, and yeast
{Saccharomyces cerevisiae) I:B..§_-H related gene c-ras-sc-1 [accession number
for RASl.

Cell lines containing the constructs were previously prepared

X00527]
and

reported by Bradley et al.{1986).
bNumbering based on sequence of EJ-ras.
cNumbering based on sequence of RASlLeudelprotein.
dAsterisk (*) on top of line

designates point of activating mutation in one or more

of the sequences. Underlined Cys near COCH-terminal end shows potential farnesylation
site.

U1
00
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Fiqure 1. Slot Blot Analysis of Mouse urokinase mRNA Levels
from NIH 3T3 Fibroblasts and ras oncoqene Transformed NIH
3T3 cell Lines.

The cells were treated with PMA (20 nM) for the
designated times, prior to total RNA extraction. The RNAs
were immobilized on a Zeta-probe filter and hybridized with
32

p-labeled mouse urokinase cDNA. Washed filter was exposed

to X-ray film.

09

61

concentrations of uPA mRNA in mouse NIH 3T3 and the ras
oncogene-transformed cells treated with 20 nM of PMA, for
the time periods indicated. On PMA treatment, increases in
uPA mRNA levels occur in the EJ/vHa-ras and EJ-ras
transformed cells as well as the untransformed NIH 3T3
cells. In contrast, the normal PMA induction of uPA was
suppressed in cells transformed by the RASl Leudel and the HYB
cLeu yeast ras genes.
The same RNA filter used in Figure 1 was rinsed and
rehybridized with a Drosophila actin probe. The filters
obtained with mouse urokinase and actin probes were traced
with a densitometer. The densitometer trace was normalized
to the actin mRNA control. Table 5 shows the average values
for uPA mRNA levels from 4 different experiments. In EJ/vHaras cells the uPA mRNA levels are 5.4-fold higher than NIH
3T3 cells with a standard deviation 1.7 at O hr PMA
treatment. The uPA mRNA of other ras transformed cell lines
at o hr PMA treatment have similar amounts within
experimental error of uPA mRNA as NIH 3T3.
With PMA treatment, uPA mRNA showed a 6-fold
induction in NIH 3T3 cells and a 2- to 3-fold induction in
both EJ-ras and EJ/vHa-ras transformed cells at 8 hours. No
induction was observed in the yeast ras transformed lines
HYB c

L~

and the RASl

~u

,

del lines.
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• sxpression of mouse cathepsin L mRNA in NIH 3T3

Fibroblasts and ras Oncogene Transformed NIH 3T3 Cell
Lines with Phorbol Ester (PMA) Treatment.

As CL was previously reported to be highly expressed
in transformed cells {Gottesman, 1988), I applied a similar
strategy as above to study the CL mRNA expression in the ras
transformed cell lines. Figure 2 shows mRNA levels for CL in
NIH 3T3 and ras transformed cell lines treated with PMA for
the times indicated. Strikingly, only in the highly
malignant .RASl

Leu

del transformed cells are the CL mRNA

constitutively expressed at high steady-state
concentrations; while in the EJ-ras and EJ/vHa-ras cells the
levels are close to one of control NIH 3T3 cells
(constitutive levels are observed at the zero time points).
In addition, Figure 2 shows that the CL mRNA levels are
strongly induced by 20 nM PMA only in the yeast
RASl

Leu

Leu

-transformed cells (HYB C

or RASl

Leu

del genes cell

lines). CL is clearly not induced by 20 nM PMA in the cells
transformed by the EJ/vHa-ras, EJ-ras, or in untransformed
NIH 3T3 cells.
The same RNA filter used in Figure 2 was rinsed and
rehybridized with the Drosophila actin probe. Densitometer
traces were normalized to the actin mRNA controls. The
experiments were run 4 times, average values of 4
independent experiments with standard deviation are
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Figure 2. Slot Blot Analysis of Mouse cathepsin L mRNA
Levels in NIH 3T3 Fibroblast and ras Oncogenes Transformed
NIH 3T3 Cell Lines.

The cells were treated with PMA (20 nM) for the
designated time, the total RNAs were extracted, the RNAs
immobilized on a Zeta-probe filter, hybridized with

32

P-

labeled mouse cathepsin L cDNA probe, and exposed to X-ray
film.
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Table

s. Levels of uPA mRNA among ras oncogene-transformed Mouse Fibroblasts
Treated with PMA and Normalized with Actina

Hours PMA Treatment

0

2

4

8

16

32

-----------------------------------------------------------------------------------b
2.0(0.7)
1.0(0.3)
3.5(0.1)
5.4(1.5)
5.5(2.1}
4.2(1.8)

NIH/3T3
EJ-ras

1.0(0.1)

1.9(0.3)

3.2(2.1)

2.7(1.2)

2.4(0.6)

1.2(0.7)

EJ/vHA-ras

5.4(1.7)

8.9(0.7)

11.5(1.7)

12.9(2.8)

10.0(4.4)

6.6(2.3)

HYB CLeu

0.9(0.3)

1.0(0.2)

1.0(0.2)

1.1(0.1)

1.4(0.4)

0.9(0.3)

RAS1 10udel

1.3(0.4)

1.1(0.1)

1.2(0.4)

1.2(0.2)

1.2(0.3)

1.3(0.3)

8

mRNAs of the cell lines were determined by slot blots analysis of total RNA (5

ug/per slot). Following autoradiography, the intensities of the slot signals were
quantified by densitometry. The results were normalized to actin, which was
hybridized and densitometrized with the same filter. The numbers are the average of 4
separate runs and standard deviation is in bracket.
bUnit is densitometeric value.
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Figure 3. Slot Blot Analysis of Mouse cathepsin B mRNA
Levels in NIH 3T3 Fibroblast and ras oncogenes Transformed
NIH 3T3 Cell Lines.

The cells were treated with PMA (20 nM) for the
designated times, total RNAs were extracted, the RNAs were
immobilized on Zeta-probe filter, hybridized with

32

p-

labeled mouse cathepsin B cDNA probe, and exposed to X-ray
film.
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Table 6. Levels of CL mRNA among ras oncogene-transformed Mouse Fibroblasts
Treated with PMA and Normalized with Actina

Hours PMA Treatment

o

2

4

8

16

32

------------------------------------------------------------------------------------1.4(0.1)
1.4{0.1)
1.5(0.2)
1.2(0.1)
1.3(0.2)
1.1(0.1)

NIH/3T3
EJ-ras

3.5(0.3)

3.1(0.3)

3.2(0.5)

3.2(0.3)

3.3(0.3)

3.1(0.2)

EJ/vHA-ras

1.8(0.4)

1.6(0.3)

1.5(0.7)

1.5(0.3)

1.6(0.4)

1.8(0.6)

HYB CLeu

1.1(0.2)

2.8(0.6)

3.4(1.3)

3.1(1.0)

1.3(0.1)

1.1(0.4)

RASlLeudel

6.1(1.1)

14.8(4.2)

12.4(4.9)

16.8(1.2)

15.0(2.7)

14.7(4.0)

amRNAs of the cell lines were determined by slot blots analysis of total RNA (5
ug/per slot). Following autoradiography, the intensities of the slot signals were
quantified by densitometry. The results were normalized to actin, which was
hybridized and densitometrized with the same filter. The numbers are the average of 4
separate runs and standard deviation is in bracket.
bunit is densitometeric value.
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displayed in Table 6. The data show that CL mRNA levels are
6 .1-fold (standard deviation 1.1) greater in RASlLeudel cells
than NIH 3T3 cells. The other transformed cell lines show
the 1.1 to 3.5-fold higher CL mRNA level than NIH 3T3 cells.
The data also show the increase of induction of CL mRNA by
PMA was 2.5- to 3.2-fold in HYB CLeu and 2- to 3-fold in
RASlLeudel at 8 hours. No apparent inductions with PMA were
observed in the EJ/vHa-ras, EJ-ras or NIH 3T3 cells.

3. Expression of Mouse cathepsin B mRNA in NIH 3T3
Fibroblasts and ras Oncogene Transformed NIH 3T3 Cell
Lines with Phorbol Ester (PMA) Treatment.

Figure 3 shows the changes in CB mRNA steady-state
concentrations under conditions of 20 nM PMA stimulation.
The changes in CB mRNA are in-between the patterns observed
for CL and uPA mRNAs. Constitutively higher levels of CB
mRNA are observed in both mammalian-like EJ-ras and
EJ/vHa-ras, and in yeast-like RASlLeudel transformed cells.
However, neither PMA induction of CB mRNA was observed in
the transformed EJ-ras cells, nor is PMA induction observed
in the untransformed NIH 3T3 controls. The same RNAs filter
was rehybridized with the Drosophila actin probe.
Densitometer traces normalized to the actin mRNA controls
and averaged over 4 independent experiments (Table 7) show
that a 2-f old increase CB mRNA is observed at 4 hours of PMA
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riqure 4. Slot Blot Analysis of Mouse Protease mRNAs Levels
from NIH 3T3 Fibroblast and ras oncogenes Transformed NIH
lT3 cell Lines after Serial Dilutions.

Total RNAs were extracted from NIH 3T3 cell and four
cell lines transfected with different ras oncogenes without
PMA stimulation. The RNAs were serially diluted and
immobilized on a Zeta-probe filter and hybridized with

32

P-

labeled mouse urokinase, cathepsin L, B and Drosophila cDNA
actin probes, and exposed to X-ray film to different times.
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Table 7. Levels of CB mRNA among ras Oncogene-transformed Mouse Fibrob1asts
Treated with PMA and Normalized with Actina

Hours PMA Treatment o

2

4

8

16

32

-----------------------------------------------------------------------------------2.8(0.5)
3.2(0.3)
3.5(0.6)
3.3(0.3)
2.9(0.3)
2.6(0.5)

NIH/3T3
EJ-ras

7.8(0.2)

6.8(1.6)

6.6(0.6)

6.5(0.3)

3.3(0.3)

3.1(0.2)

EJ/vHA-Il.§_

5.4(0.3)

12.5(2.0)

12.8(2.4)

9.8(0.7)

8.5(0.8)

5.9(1.0)

HYB CLeu

2.4(0.1)

10.3(3.7)

9.9(2.7)

10.2(0.4)

3.6(0.1)

1.1(0.4)

RASlLeudel

4.2(0.3)

12.8(9.4)

12. 1 ( 5. 0)

12.3(1.1)

11. 0 (2. 5)

6.3(2.8)

8

mRNAs of the cell lines were determined by slot blots analysis of total RNA (5

ug/per slot). Following autoradiography, the intensities of the slot signals were
quantified by densitometry. The results were normalized to actin, which was
hybridized and densitometrized with the same filter. The numbers are the average of 4
separate runs and standard deviation is in bracket.
bUnit is densitometeric value.
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stimulation in cells transformed with
mammalian-likeEJ/vHA-ras and the increase persisted for upto

s hours. CB mRNA concentration increased 4-fold at between 2
Leu
and 8 hours after PMA stimulation in HYB C
transformed
cells and 3-fold during that same period in RASlLeudel
transformed cells.
To order to demonstrate that conclusions from the
slot blots above are not caused by over-saturating the
filter membrane, the RNA samples (without PMA stimulation)
were serially diluted from 1 to 4 ug per slot. The filters
were hybridized with the cDNA probes under the identical
conditions as above. The results are shown in Figure 4. Just
as previously described, the highly malignant
EJ/vHa-ras-transformed cells show a higher constitutive
level of uPA mRNA over NIH 3T3 controls and other ras
oncogene-transformed cells. The CL mRNA is constitutively
expressed at the highest steady-state concentrations in the
highly malignant RASlLeudel transformed cells. Densitometer
analysis of the blots confirms the relative concentrations
previously described.
To further confirm the results of the slot blots for
CL, Northern blots were carried out. The Northern not only
compares the concentrations of mRNAs, but also demonstrates
the molecular weights of the mRNAs. Cytoplasmic RNAs were
isolated from cell cultures without PMA treatment, and the
poly(A)+ mRNAs were obtained with a poly(dT) column. The
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Figure

s. Northern Blot Analysis of Mouse Cathepsin L mRNA

Levels from NIH 3T3 Fibroblast and ras Oncogenes Transformed
NIB 3T3 Cell Lines.

+

Poly(A) mRNAs were extracted from NIH 3T3 cell and
four other cell lines transfected with different ras
oncogenes. The RNAs were separated by electrophoresis
through 1% agarose gel. The RNAs were transferred onto zetaprobe filter, hybridized with

32

P-labeled mouse cathepsin L

cDNA probe (top) or GAPD (bottom), and exposed to X-ray
film.
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mRNAS were separated by electrophoresis through a 1% agarose
gel . The RNAs were transferred onto a Zeta-Probe filter and
hybridized with a

32

P-labeled mouse cathepsin L cDNA probe.

The result is displayed on Figure 5. In this figure, only
1

the RAS1 eudel transformed cells show highest expression
among the other cell lines. Other observations are also
consistent with those obtained in the slot blot analyses,
described above. The molecular weight of the CL mRNA blotted
is 1.8 to 2.0 kilobase (kb), which is consistent with the
literature (Troen et al., 1987).

4. comparison of Transcription Rates of uPA, CB and CL
with and without PMA stimulation in NIH 3T3
Fibroblasts and ras oncogene Transformed NIH 3T3 Cell
Lines

The induction of the protease mRNA levels could be
the result of either increases in transcription rates or
decreases in mRNA degradation rates. In order to further
investigate the mechanism of induction, run-on assays were
carried out. The nuclei of the cell were isolated from the
cells in culture either with 20 nM PMA for 2 hours or
without PMA treatment. The nuclei were incubated with

32

P-

UTP. The labeled RNAs were isolated and hybridized to the
protease cDNA plasmids immobilized on a nitrocellulose
filter. The filters were washed and exposed to X-ray film.
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The results are displayed on Figure 6. Of the 3 cell lines
studied, the CL gene transcription rate shows a much higher
transcription rate and PMA inducibility only in the yeast
RASl Leudel transformed cells. PMA stimulation of CL

=-

transcription is not observed in the EJ/vHA-ras transformed
or untransformed NIH 3T3 fibroblasts. CB transcription rates
show a mild increase in both the RASl Leudel transformed cells
and the EJ/vHA-ras transformed cells on PMA stimulation, but
shows no PMA stimulation in the untransformed NIH 3T3 cells.
The transcription rate of the uPA gene is higher in the
EJ/vHa-ras transformed cell than the NIH 3T3 cells, uPA gene
transcription rate in the RASl Leudel cells is not
significantly different from one in NIH 3T3. In addition,
PMA shows a significant increase in uPA gene transcription
in the untransformed NIH 3T3 cells and in the EJ/vHA-ras
transformed cells, but no PMA stimulation of transcription
Leu
rate is observed in the RASl del-transformed
cells.
Results from the densitometer traces of the run-on
assays are shown on Table 8. The data shows that the CL gene
transcription rate in RASlLeudel cells was 6-fold greater
than in NIH 3T3 cells, and PMA causes a further 2-fold
increase of CL gene transcription rates was observed in
RASl Leudel-transformed cells. CL transcription rate are not
PMA stimulated in NIH/3T3 or EJ/vHa-ras-transformed
cells.The uPA transcription rate was 7-fold higher in
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riqure 6. The Run-on Assays of uPA, CB and CL with and
without PMA Stimulation in NIH 3T3 cells, EJ/vHa-ras and
~lL~del-transformed Cells.

The nuclei were isolated from the cell cultures with
pMA treatment (20 nM, 2 hours) or without PMA treatment.
Nuclei were incubated with

32

P-UTP, and RNAs were isolated,

and hybridized to the cDNAs for uPA, CB and CL immobilized
on a nitrocellulose paper. The filters were washed and
exposed to X-ray film.

CL

CB

.....
UK

CL
CB

UK
llClin
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TABLE 8 Relative mRNA Transcription Rates
by Run-on Assay•
A. No PMA treatment
CELL LINES
GENE ASSAYED

RAS 1L8'1>EL

NIH/3T3

EJ/vHA-ras

CL

0.89

2.38

5.24

CB

0.86

0.91

1.61

uPA

0.10

0.72

0.13

ACT IN

0.31

0.33

0.30

B. Treatment with PMA (20

nM)

for 2 hours

CELL LINES
GENE ASSAYED

NIH/3T3

EJ/vHA-ras

RAS1Le~EL

CL

0.93

2.02

9.61

CB

0.90

1.81

2.70

uPA

0.39

2.75

0.15

ACT IN

0.28

0.35

0.29

'Values from desitometer trace of autoradiography.
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EJ/vHa-ras-transformed cells than in untransformed NIH 3T3
cell. PMA treatment caused a further 4-fold stimulation of
transcription rate in untransformed NIH 3T3 cells and in
EJ/vHa-ras-transformed cells. The uPA gene transcription
Leu
rate was not elevated in the RASl del cell nor was uPA
transcription

stimulated by PMA in this cell line. The

results of the run-on assays mimic the changes observed in
steady-state mRNA concentrations in Figures 1, 2 and 3, and
demonstrate that the differences observed in the
constitutive steady-state mRNA levels and with PMA
stimulation for the different ras-transf ormations are
primarily due to increases in transcription rates and not to
differences in mRNA stability.

s. Determination of uPA Enzymatic Activities of conditioned
Media from NIH 3T3 Fibroblasts and ras oncogene
Transformed NIH 3T3 Cell Lines Treated with
Oligonucleotides

Based on the observation that uPA mRNA is highly
expressed in the cells transformed with the EJ/vHA-ras,
while cathepsin

L

mRNA is highly expressed in the cells

transformed with RASlLeudel gene, it would be of interest to
test the possibility of different involvements of uPA and CL
in a metastatic assay.
Anti-sense oligodeoxynucleotides are short synthetic

82
nucleotide sequences formulated to be complementary to a
specific gene or RNA message. Through the binding of these
oligomers to a target sequence in a cell, transcription or
translation of the gene can be selectively blocked. A number
of studies were completed with oligodeoxynucleotides
(reviewed by Rothenberg et al., 1989), which suggests that
antisense deoxyoligonucleotide inhibitors may be also able
to selectively inhibit the urokinase and CL gene expressions
in the ras oncogenes transformed cell lines. If antisense
oligonucleotide could inhibit CL and uPA gene expressions,
then the cells could be then injected into nude mice to
determine the effect of selectively inhibiting uPA and CL
gene expressions on experimental metastasis.
Three 21-mer oligonucleotides used in this work were
sense-uPA (5'-ATGAAAGTCTGGCTGGCGAGC-3'), anti-uPA (5'GCTCGCCAGCCAGACTTTCAT-3'), and anti-CL (5'CAAAAGGAGTAAAAGATTCAT-3'). The optimum concentration to
achieve the maximal inhibition was determined by varying the
concentration of the oligo. The secretion of uPA and CL
activity into the cell culture medium after removal of these
oligonucleotide inhibitors were quantified by chromogenic or
fluorogenic substrate assays (discussed in the following
paragraphs). A concentration of 10, 20, 50, 100, 200

uM

was

tested for each of the antisense oligonucleotides, and the
optimum concentration to achieve the maximal inhibition was
found to be 100

uM

for both ant-uPA and anti-CL (Table 9).
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This concentration was the one used in the following
inhibitory studies with these oligos.
The secretion of uPA activity into the cell culture
medium after removal of the oligonucleotide inhibitors was
quantified by measuring plasmin activities following the
activation of plasminogen to plasmin by the urokinase. Cells
were plated into wells and incubated in complete media
containing 10% FBS and the different oligos (100 uM) for 24
hr as described in methods. The media was removed. The cells
were then incubated in serum-free, oligo-free media. This
medium was replaced every 12 hrs for upto 48 hrs. The media
samples were assayed for secreted uPA enzyme activity.
Figure 7 is a demonstration of uPA activities of
these cell lines treated with three oligos. EJ/vHa-ras has
the highest uPA enzymatic activity of these cell lines.
Anti-uPA inhibited secreted activity by approximately 45% in
all cell lines. The inhibition lasted for at least 48 hours
after removal of the antisense oligo from the media. uPA
sense oligo has no obvious effect on the uPA enzymatic
activities of these cell lines.
Table 10 gives the numbers plotted in Figure 8 and
shows that without the oligonucleotide inhibitor, NIH 3T3
cells displayed a uPA enzymatic activity corresponding to an
absorbance 1.36 per hour per 10 6 cells for the first 12
hours. This is equal to the activity level of RASlLeudel,
whereas EJ/vHA-ras cells showed about a 3-fold higher uPA
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Fiqure 1. uPA Enzymatic Activities of conditioned Media from
NIH 3T3 Fibroblasts and ras oncogene Transformed NIH 3T3
cell Lines on Treatment with

Oligodeoxynucleoti~es.

Cells were plated into wells and incubated in
complete media containing 10% FBS and oligo (100 uM) for 24
hr. The media was removed and the cells were incubated in
serum-free, oligo-free media which was removed from cells
every 12 hrs up to 48 hrs and assayed for secreted enzyme
activity.
Asterisk (*) on the top of the bars designated
specific condition with significant difference from the
control group (no oligo treatment).
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enzymatic activity. The difference in activity levels are in
the direction expected from their respective mRNA levels and
gene transcription rates, previously determined. Treatment
with sense-uPA oligo caused no apparent change in uPA
enzymatic activities in these cell lines studied.

6. Determination of CL Enzymatic Activities of Conditioned
Media from Mouse NIH 3T3 Fibroblast and ras oncogene
Transformed NIH 3T3 Cell Lines Treated with
Oligonucleotides.

CL enzymatic activities were determined against the
substrate N-carbobenzoxy-L-Phe-L-Arg-7-aminomethylcoumarin
(Z-Phe-Arg-AMC) • Total enzymatic activity was first
determined both in secreted medium and in membrane
associated components. The results are shown in Table 11. As
the results show the cells-associated activity is only 11-25
% of total enzymatic activities, the following assays to

test inhibitory activities of the oligonucleotide antisense
were carried out only on the secreted medium.
The results are displayed in Figure 8. Obviously,
RA
__Ql

Leu

del cells has the highest CL enzymatic activity among

the cell lines. Anti-CL inhibited secreted activities by
about 35% in all cell lines, and its inhibitory effect
lasted for 24 hours after removal of the antisense oligo.
UPA sense oligo has no noticeable effect on the CL enzymatic
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Table 9. concentration Dependence of Oligonucleotides
Inhibitory Effects

8

EJ-vHa-ras Cells

uPA activity

anti-uPA concentration
no oligo
10 uM
20 uM
50 uM

100 uM
200 uM

4. ab

co. 9)

4.6
4.2
3.7
2.7
2.6

(1.0)
(0.9)
(0.8)
(0.7)
(0.5)

% inhibition

0

10
13
23
44

45

----------------------------------------------------------RASl Leudel Cells

anti-CL concentration

CL activity

no oligo

78.2d
75.4
71.3
58. 6
50.8
51.3

10 uM
20 uM
50 uM

100 uM
200 uM
8

% inhibition

(15.2)
(15.7)
(13.8)
( 11. 4)
(9.9)

(11.1)

4
9

25
35
34

Enzymatic activities were determined with the first 12 hour
serum-free medium after removal of the oligo inhibitors.

buPA enzymatic activities were determined with the chromogenic
substrate S-2551. Numbers are the average of 3 separate runs
6

with units of O.D. per 10 cells per hour
0

d

The number in bracket is standard deviation.
CL enzymatic activities were determined by substrate Ncarbobenzoxy-L-Phe-L-Arg-7-aminomethylcoumarin (Z-Phe-Arg6

AMC) with units of pmol/min/10 cells.
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riqure s. Cathepsin L Enzymatic Activities of Conditioned
Media from NIH 3T3 Fibroblasts and ras Oncogene Transformed
NIH 3T3 Cell Lines on Treatment with Oliqodeoxynucleotides.

Cells were plated into wells and incubated in
complete media containing 10% HI-FBS and oligo (100

uM)

for

24 hr. The media was removed and the cells were incubated in
serum-free, oligo-free media which was removed from cells
every 12 hours up to 48 hours and assayed for the secreted
enzyme activity.
Asterisk (*) on the top of the bars designated
specific condition with significant difference from the
control group (no oligo treatment).

89

NIH/3T3

20

~cell alone

(/)

Q)

>u

·so
·- ......

o-c
ca ·-

~ sense uPA

,5

~ anti-sense CL

,0

E
u::::
...1

0

E

5

c.

0-, 2

35
.!!J.
Qi

30

·s:... "'0......
·...

25

..J E
u::::0

15

>u

--

c:
ca ·-

u

E

c.

, 2-24

24-36

36-48

EJ/vHa-ras
~cell alone
~ sense uPA
~ anti-sense CL

20
10

5

0

L____k'.~~____.!~~____.!~~_JCLl:::,l~l.__~.L

0-12

12-24

RAS 1

24-36

Leu

36-48

del
~cell clone

.!!J.
Qi

80

~ sense uPA

>u

~ anti-sense CL

·SO so
!'.:
~ .!:

.+:i
..J

E

u ~

40
20

c.

0

0-12

12-24

24-36

36-48

TIME (hours)

90

activities of these cell lines under the experimental
conditions.
The values plotted in Figure 8 are given in Table 12
for the anti-CL oligo inhibitory effects on the cell lines.
without oligonucleotide inhibitor, NIH 3T3 cells showed an
activity of 16.8 pmol/min/102 cells with a standard
deviation 1.4 in the first 12 hrs. EJ/vHA-ras secreted about
1.6-fold more CL enzymatic activity than NIH 3T3, whereas
RASlLeudel cells showed a 4. 8-fold higher CL activity than
NIH 3T3. CL enzymatic activities in all of the these cell
lines was not significantly decreased after treatment with
the sense-uPA oligos from the activity under non-oligo
treated condition. Treatment with anti-CL decreased the CL
activity from 33 to 39 % for up to 24 hours. After 24 hours
the inhibitory effects of the oligos lessened. At 48 hours
after removal of oligo, the inhibitory effect of the anti-CL
was not significant.

7. Investigation of Tumor Metastatic Potentials by Lung
Colonization Assay

It has been concluded by several investigators that
the critical timing for lung colonization in the tail vein
assay of metastasis is the first 12 hours following the
injection of tumor cells into mice (Fidler, 1978; Humphries
et al., 1986; Morikawa et al., 1988). It was observed that
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the antisense oligonucleotides have an inhibitory effect on
uPA and CL enzymatic activities, and the inhibitory effects
of the antisense oligos lasted at least 24 hours after
removal of oligonucleotide antisense inhibitors from the
cell culture media. Thus, the duration of inhibition falls
within the critical time frame for the tail-vein assay of
metastasis.
In experiment one, EJ/vHA-ras cells were treated in
vitro with the oligonucleotides for 24 hours and the oligo
treated tumor cells (3x10

5

)

were injected into the tail

veins of 4 - 6 week athymic (Ncr nu/nu) female mice. The
mice were sacrificed 14 days later. Lungs were dissected
from the mice and the number of surface tumors per lung
counted. The results are shown in Table 13. With the sense
uPA oligonucleotide treatment (control), injected tumor
cells produced an average of 130 tumors per lungs. With
anti-CL oligonucleotide treatment, the injected EJ/vHa-ras
tumor cells produced an average of 122 tumors per lungs
which is not significantly different from the control
treated cells, even though CL activity had been decreased
35% by the antisense treatment. With anti-uPA treatment (uPA
activity was lowered 45%), the injected tumor cells produced
an average of 41 tumors per lung, significantly below the
control group (p <0.001).
In experiment two, RAS1 18udel cells were treated with
the same oligonucleotides. The treated cells were injected
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into nude mice and the results are also shown in Table 13.
The results show that with the sense uPA oligonucleotide
treatment (for control), injected tumor cells produced an
average of 94 tumors per lung. With anti-CL oligonucleotide
treatment (CL enzymatic activities was lowered about 35%),
the cells produced an average of 26 tumors in lung (p < 0.01
with respect to control). With anti-uPA treatment (uPA
activities was lowered by 45%), the injected tumor cells
produced an average of 81 tumors per lungs, not
significantly different from the control group.
The work on RASl

Leu

del cells were repeated once, and

the results are displayed on Table 14. With the sense uPA
oligonucleotide treatment (control), the injected tumor
cells produced tumors with average 76 per lung. With anti-CL
oligonucleotide treatment, the injected RASl

Leu

del cells

produced 29 tumors per lungs (p <.05 by Student' T test; p>
.05 by nonparametric Wilcoxon rank sum test). With anti-uPA
oligonucleotide treatment, the injected cells produced 65
tumors per lung, not significantly different from the
control group.
The results from the nude mice experiments suggest
that either high levels of uPA or CL are induced by
different ras oncogene transformations, and uPA and CL may
substitute for each other in the lung colonization
processes.

Table 10 uPA secreted Enzymatic Activity of ras-transformed Cell
Lines Treated with Sense- and Anti-sense Oligonucleotides
NIH/3T3

sense-uPA
(100 uM}

anti-sense uPA

% inhibition

(100 uM}

of uPA
activity

Time after
removal of
oligo

no oligo

12-24 hr

1.2 (0.1)

1.13 (0.06}

0.61 (0.03}

47

24-36 hr

0.80 (0.06}

0.75 (0.06}

0.43 (0.03}

44

36-48 hr

0.65 (0.04}

0.66 (0.06}

0.34 (0.04)

46

----------------------------------------------------------------------------------1. 36a (0.06}b
49
0-12 hr
1.23 (0.06}
0.70 (0.02}

EJ/vHA-ras

sense-uPA

no oligo
(100 uM}

12-24 hr

3.6 (0.2}

3.3 (0.2}

1.9 (0.2}

45

24-36 hr

3.1 (0.2}

3.0 ( 0 .1)

1. 7 (0.2}

45

36-48 hr

2.6 ( 0 .1)

2.3 (0.1}

1.4 (0.2}

44

(100 uM}

anti-sense uPA
of uPA

% inhibition

Time after
removal of
oligo

activity

---------------------------------------------------------------------------------------47
2.3 (0.2}
0-12 hr
4.3 (0.2}
4.4 ( 0. 2}

-----------------------------------------------------------------------------------""\()w

Table 10.

(continued)

RASlLeudel

sense-uPA
(100 uM)

anti-sense uPA
(100 uM)

% inhibition

1.1 (0.1)

1.2 ( 0 .1)

0.61 (0.02)

45

12-24 hr

0.85 (0.02)

0.87 (0.01)

0.55 (0.03)

44

24-36 hr

0.72 (0.02)

0.71 (0.01)

0.38 (0.03)

47

36-48 hr

0.63 (0.02)

0.63 (0.01)

0.34 (0.02)

45

Time after
removal of
oligo

no oligo

0-12 hr

of uPA
activity

-----------------------------------------------------------------------------------uPA enzymatic activities were determined by chromogenic substrate S-2551.
a

bNumbers are the average of 3 separate runs with units of O.D. per 10
The number in bracket is standard deviation.

6

cells per hour.
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Ta~le 11 CL Enzymatic Activity of ras-transformed Cell Linesa

Medium

Cells-ass.

Total

Cells-ass.
/Medium

----------------------------------------------------------18.6
3.4
22.0
0.18

NIH/3T3

19.5
20.1

4.3
5.2

23.8
25.3

0.22
0.25

EJ/vHa-ras

28.6
30.8
31.5

3.1
4.7
3.8

31. 7
35.5
36.3

0.11
0.15
0.12

RAS1 19udel

77.4
80.1
81.8

14.1
15.7
15.4

91.5
95.8
97.2

0.18
0.20
0.19

aCL enzymatic activities were determined by substrate Ncarbobenzoxy-L-Phe-L-Arg-7-aminomethylcoumarin (Z-Phe-Arg-AMC)
with units of pmol/min/10

6

cells.

Table 12 CL Enzymatic Activity of ras-transformed Cell
Lines Treated with Anti-CL Oligonucleotide
NIH/3T3

Time after
removal of
oligo

no oligo

sense uPA

anti-CL

% inhibition

(100 uM)

(100 uM)

of CL
activity

---------------------------------------------------------------------------------------0-12 hr
16. 8 (2.4)b
14.9 (2.6)
10.2 ( 1. 4)
39
8

12-24 hr

13.1 ( 2. 3)

12.1 (1. 5)

6.6 ( 1. 4)

34

24-36 hr

9.6 ( 1. 3)

9.4 ( 1. 5)

7.3 ( 1. 2)

23

36-48 hr

8.2 ( 1. 4)

8.3 ( 1. 3)

6.9 ( 1. 3)

15

EJ/vHA-ras

Time after
removal of
oligo

no oligo

sense uPA
(100 uM)

anti-CL
(100 uM)

~
0

inhibition
of CL
activity

----------------------------------------------------------------------------------------0-12 hr
26.4 (3.8)
27.2 (3.7)
16.9 ( 3. 6)
36
12-24 hr

21. 6 (3.3)

21. 0 (3.3)

14.4 (3.4)

33

24-36 hr

18.2 (2.2)

18.3 (2.2)

14.4 ( 2. 2)

20

36-48 hr

13.7 (2.5)

12.9 ( 2. 1)

11.8 (2.4)

14

----------------------------------------------------------------------------------------'°
O'I

Table 12.

(continued)

RASlLeudel

no oligo

sense uPA
{100 UM)

anti-CL
(100 uM)

%inhibition
of CL
activity

0-12 hr

73.4 ( 11.1)

69.8 (15.4)

47.6 ( 8. 5)

35

12-24 hr

52.3 ( 11. 0)

49.1 (12.9)

34.2 ( 6 .1)

34

24-36 hr

42.0 (9 .1)

42.4 (13.1)

35.3 (5.4)

15

36-48 hr

34.2 (5.8)

33.7 (5.3)

34.3 (6.5)

8

Time after
removal of
oligo

----------------------------------------------------------------------------------------enzymatic activities were determined by substrate N-carbobenzoxy-L-Phe-L-Arg-7-

a CL

aminomethylcoumarin (Z-Phe-Arg-AMC). Numbers are the average of 3 separate run with units of
pmol/min/10

6

cells.

bThe number in bracket is standard deviation.
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Table 13. Lung Colonization of Nude Mice by ras-transtormed
NIH 3T3 cells Selectively Inhibited by Antisense Oligos•

oligo

-----

Mean ± s.o.

Number of tumors/Lung

------

---------------------

EJ/vHa-ras-transtormed NIH 3T3 Cells
sense-uPA

105, 113, 115, 121, 137
139, 143, 166

130 ± 20

anti-CL

69, 85, 102, 104, 117
137 147, 213

122 + 45

anti-uPA

27, 29,
52, 68

32, 42,

41 + 14b

45

Rasl Leudel-transtormed NIH 3T3 Cells
sense-uPA

48, 63, 78, 87, 129, 159

94 + 38

anti-CL

18, 21, 23, 27,

26 + 6c

anti-uPA

38, 47, 56, 78, 86, 94, 170

aOligo treated tumor cells (3x10

5

)

31,

35

81 + 44

were injected into the tail

veins of 4 - 6 week athymic NCr (nu/nu) female mice, and the
mice were sacrificed 14 days later. Lungs were disected from
mice and the number of surface tumors per lung counted.
bsignificantly different from other groups at p < 0.001 by
nonparametric Wilcoxon rank sum test.
0

Significantly different from other groups at P < 0.01 by
nonparametric Wilcoxon rank sum test.
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Table 14. Lung Colonization of Nude Mice by RASl LeudelTransformed Cells Selectively Inhibited by Antisense Oligosa
(Experiment 2)
Oligo

-----

sense-uPA

Mean + S.D.

Number of tumors/Lung

------

--------------------10, 37, 82, 85, 112, 130

anti-CL

9, 18, 22, 29,

anti-uPA

11, 34, 44, 69,

32,

35,

76 + 45
60

92, 101, 107

29 ± 16b
65 ± 37

aoligo treated tumor cells (3x10 5 ) were injected into the
tail veins of 4 - 6 week athymic NCr (nu/nu) female mice,
and the mice were sacrificed 14 days later. Lungs were
disected from mice and the number of surf ace tumors per lung
counted.
bSignificantly different from other groups at p < 0.05 by
Student' t test. No significantly different from other groups
by nonparametric Wilcoxon rank sum test.
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• phorbol Ester Induction of Proteases and Protease

Inhibitors in Buman Prostate carcinoma Cell Lines PC3-P
and PC3-M

In addition to work done on the mouse NIH JTJ cell
lines, phorbol ester response was also studied in two pairs
of related human cell lines of different metastatic
potential. The major properties of these cell lines have
been described in the Methods Section.
The PCJ-M (metastatic) cell line was isolated from
the PCJ-P {parental) and shows a significantly greater
ability in both spontaneous metastasis and lung colonization
than the PCJ-P cells (see Table 2)

(Kozlowski et al., 1984).

Figure 9 and 10 show that phorbol ester induces both the uPA
mRNA and PAI-2 mRNA levels in PCJ-P and PCJ-M cells. The
mRNA induction follows a time course in which mRNA levels
increase between 4 and 16 hours, and then decrease by 32
hours to basal levels. At all time points, uPA and PAI-2
mRNA levels were compared to that of glyceraldehyde
phosphate dehydrogenase {GAPD) mRNA which is not stimulated
by PMA in these cell lines and therefore serves as a
control. In contrast to the results with ras-transformed
NIH/3T3 cells, in PCJ cells, the increased ability of the M
lines to metastasize may correlate most closely with a
decreased induction of PAI-2 mRNA levels when compared with
the P lines (parental, low metastatic potential) rather than

101
with an increase in uPA mRNA levels in the M lines.
stimulation of uPA mRNA in PC3-M cells was only 1.2-fold
over that of the PMA stimulation of uPA mRNA levels in PC3-P
cells. However, on PMA induction, the PAI-2 mRNA reached
levels 6-fold higher in PC3-P (low metastatic) than in PC3-M
cells (highly metastatic). GADP was not significantly
induced at the identical conditions. Densitometer traces
normalized to the GADP mRNA controls and averaged over 3
independent experiments are shown in Table 15. There is no
PAI-2 detected in either PC3 - P or PC3-M prior to
stimulation. PAI-2 mRNA was induced by 2 hours in both PC3-P
and PC3-M lines, and reached peaks of 3.32 densitometeric
units (S.D.± 0.8) in PC3-P cells and 0.56 densitometeric
units (S.D.± 0.07) in PC3-M cells, respectively by 8 hours.
No apparent inductions with PMA were observed in the GAPD
mRNA.
To verify the results for PAI-2 from these slot blot
analyses, a Northern blot analysis was carried out to study
the PAI-2 mRNA levels from PC3-P and M cell lines. The
result is displayed in Figure 11. Without PMA stimulation,
no PAI-2 was detected in either cell line (lanes 1 and 3).
Under PMA stimulation (20 nM) for 8 hours, PAI-2 could be
detected in both cell lines, the P line (lane 4) showed
significantly higher PAI-2 level than the M lines (lane 2).
PMA induction of mRNA levels can take place through
either induction of new protein(s)

(transcription factor
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Fiqure 9. Slot Blot Analysis of Human uPA and PAI-2 mRNA
Levels in PC3-P Cells with PMA Treatment.

The PC3-P cells were treated with PMA (20 nM) for
the designated times and total RNAs were extracted. The RNAs
were immobilized on a Zeta-probe filter, hybridized with the
32

p-labeled human uPA, PAI-2 and GAPD cDNA probes, and

exposed to X-ray film.
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piqure 10. Slot Blot Analysis Of Human UPA and PAI-2 mRNA
Levels in PC3-M Cells with PMA Treatment.

The PC3-M cells were treated with PMA (20

nM)

for

the designated times and total RNAs were extracted. The RNAs
were immobilized on a Zeta-probe filter, hybridized with the
32

p-labeled human uPA, PAI-2 and GAPD cDNA probes, and

exposed to X-ray film.

HOURS (PMA TREATED)

0

2

4

8

16

32

PAl-2

uPA

GAPD

PC3-M CELLS

Table 15. Levels of Human uPA and PAI-2 mRNA
in PC3-P and PC3-M with PMAa
PC3-P
Hours PMA Treated

2

0
b

uPA/GADP

0.55 (.12) 1.63(.22)

N.O.

PAI-2/GADP

b

0.61(.17)

4

2.34(.4)
1.27(.31)

16

8

1.82(.32)
3.32(.76)

1.28(.24)
1.21(.28)

32
0.52(.14)

N.O.

PC3-M
Hours PMA Treated
uPA/GADP

0.92(.21)

PAI-2/GADP
8

0

N.O.

16

32

2

4

8

1.12(.20)

1.61(.35)

2.41(.72)

2.91(.55)

0.85(.19)

0.22(.04)

0.32(.08)

0.56(.07)

0.28(.03)

N.O.

mRNAs of the cell lines were determined by slot blots analysis of total

RNA (4 ug/per slot). Following autoradiography, the intensity of the each slot signal
was quantified by densitometry. The results were normalized to GADP, which was
hybridized and densitometrized with the same filter. The numbers are the average
densitometeric value of 3 separate runs and standard deviation is in bracket.
b

Not observable.

.......
0
O'I
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Fiqure 11. Northern Blot Analysis of Human PAI-2 and TIMP
JDRNA Levels from PC3-P and PC3-M Cells with PMA Treatment.

Total RNAs were extracted from human prostate
carcinoma PC3-P and PC3-M cell lines with and without PMA
(20 nM} treatment. The RNAs were separated by
electrophoresis through a 1% agarose gel. The RNAs were
transferred onto a Zeta-probe filter, hybridized with

32

P-

labeled human PAI-2 and TIMP inserts. The resulting filter
was exposed to X-ray film.
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Fiqure 12. Northern Blot Analysis of Human UPA mRNA Levels
in PC3-P and M Cell Lines with PMA as well as Cycloheximide
Treatment.

Total RNAs were extracted from human prostate
carcinoma PC3-P and PC3-M cell lines after incubation with
PMA (20 nM) and/or cycloheximide. Lanes 1 and 5: without
treatment of PMA and cycloheximide (CHX); lanes 2 and 6:
treatment with PMA for 16 hours; lanes 3 and 7: treatment
with PMA (20 nM) and CHX (10 mg/ml) for 16 hours; lanes 4
and 8: treatment with CHX (10 mg/ml) for 16 hours. The RNAs
were separated by electrophoresis through a 1% agarose gel.
The RNAs were transferred onto a Zeta-probe filter,
hybridized with the

32

P-labeled human plasmid uPA insert,

and exposed to X-ray film.
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activators) or by a direct stimulation of mRNA synthesis
through activation of factors that do not require new
protein synthesis. To explore these different alternatives,
cycloheximide (10 mg/ml), a protein synthesis inhibitor, was
added to the cell culture medium for 16 hours. Its effect on
PMA induction was followed by a Northern blot analysis of
uPA mRNA, shown in Figure 12. Lanes 1 and 5 contain mRNAs
isolated from PC3-P and PC3-M cells respectively without
prior PMA and represent basal levels of uPA mRNA. PMA
induced uPA mRNA expression in both cell lines (lane 2 and
6), and cycloheximide added to the cell culture medium
together with PMA (lanes 3 and 7) enhanced uPA mRNA still
further in both cell lines. Cycloheximide (lanes 4 and 8)
alone had no inductive effect.

9. Phorbol Ester Induction of Protease Inhibitor in Human
Melanoma Cell Lines A375-P and A375-SM

The A375-P is a human melanoma cell line with low
metastatic potential. A375-SM was isolated from the A375-P
and it shows a substantially greater ability to metastasize
as measured by a lung colonization assay (see Table 2).
These cell lines were treated with PMA as described above
for PC3-P and PC3-M cells. Figure 13 is the Northern blot
analysis of PAI-2 with and without PMA treatment. PAI-2 mRNA
could not be detected in either A375-P and A375-SM cell
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lines two hours after treatment PMA (20 nM), but then
increased to high levels in A375-P between 8 and 16 hours
(Figure 15). In contrast, PAI-2 mRNA was only barely
detectable after 16 hr PMA treatment in A375-SM cells under
identical conditions (Figure 13). The values from the
densitometer traces normalized to the GADP mRNA controls are
displayed in Table 16. The amount of PAI-2 produced by A375P was 0.82 densitometer units at 8 to 16 hours, whereas PAI2 levels in A375-SM only 0.12 and 0.05 densitometer units at
the same time points, respectively. Maximum levels of PAI-2
mRNA were 16-fold higher in the A375-P cells (low
metastatic) than in the A375-SM cells (highly metastatic).
In order to follow PMA induction at the protein
level, a Western blot analysis of human PAI-2 in the two
human melanoma cells A375-P and SM was carried out. Proteins
were collected from the cell culture media. Cells were lysed
and homogenized and the protein concentration of each sample
determined with the BCA assay (Pierce Chemical Company,
Rockford, Ill.). Ten mg of protein were loaded into each
slot of SDS-PAGE gel and electrophoresed. The protein then
were transferred to a nitrocellulose filter (Bio-Rad) and
PAI-2 was detected with polyclonal antibodies against human
PAI-2 (American Diagnostica Inc., New York, NY). The details
of the assay are discussed in the Methods Section. The
results are displayed in Figure 14. No PAI-2 was detected in
either A375-P or A375-SM cell lines prior to PMA treatment.
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Figure 13. Northern Blot Analysis of Human PAI-2 and TIMP
mRNA in A375-P and A375-SM Cells with PMA Treatment.

Total RNAs were extracted from human melanoma cells
A375-P and SM cells with and without PMA (20 nM) treatment.
The RNAs were separated by electrophoresis through a 1%
agarose gel. The RNAs were transferred to a Zeta-probe
filter and hybridized with the

32

P-labeled human PAI-2 and

TIMP plasmid inserts. The resulting filter was exposed to Xray film.
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Table 16. Levels of PAI-2 mRNA in A375-P and SM Cells
with PMA Treatment Normalized to GAPDa

Hours PMA Treated

2

0

A375-P

N.O.

A375-SM

N.O.

b

4

8

16

N.O.

0.12

0.82

0.82

N.O.

N.O.

N.O.

0.12

32
0.49

0.05

amRNAs of the cell lines were determined by Northern blots analysis of total
RNA (20 ug/well). Following autoradiography, the intensity of the signals was
quantified by densitometry. The results were the densitometeric value of PAI-2
normalized to the densitometeric value of GADP, which was hybridized with the same
filter.
bNot observable.
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With PMA (20 nM) incubation for 24 hours, both cell lines
produced detectable PAI-2 with the P line giving a higher
amount than the SM line. Two bands are shown in the Figure
14, a low Mr band of about 48 kD, and a high Mr band of 96
kD. The 48 kD band is ostensibly PAI-2 protein (Kruithof et
al., 1986). The nature of 96 kD band is not clear. The high
molecular weight band, most likely, is a complex formed
between PAI-2 and uPA. A similar finding was also reported
from other laboratories (Nelson et al., 1986).
10. Induction of PAI-2 in Human Prostate Carcinoma Cell
Lines PC3-P and PC3-M with conditioned Media

The surprising observation that PMA induction of PAI2 may more closely correlate with metastatic potential than
the uPA protease activity suggests that gene expressions of
both protease and protease inhibitors might be altered by
growth factors in vivo. As PMA is a compound which does not
exist in the living animal, conditioned media containing
putative growth factors was collected from mouse organs
explants for 24 hours. The details of media collection are
discussed in the Methods Section. The conditioned medium was
used to replace PMA in treating PC3-P and PC3-M cell lines.
PAI-2 gene expression was measured by a Northern blot
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Figure 14. Western Blot Analysis of Human PAI-2 Protein in
pc3-P and M Cells with PMA Treatment

Ten mg of the proteins sample was loaded into each
slot of a SDS-PAGE gel, and separated by electrophoresis.
The proteins were transferred to a nitrocellulose filter.
PAI-2 polyclonal antibody was used as a primary antibody,
followed by goat anti-mouse antibody {Sigma Chem. Co.)
conjugated with alkaline phosphatase.
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analysis. The result is displayed in Figure 15. No PAI-2
mRNA was detected in either PC3-P and M cells cultured in
normal medium (lanes 1 and 5) and in conditioned medium from
kidney (lanes 3 and 7), and spleen conditioned medium (lanes
4, 8). However, incubation of the cells with conditioned
medium from the lung organ culture showed a stimulating
effect. Both PC3-P and M produced PAI-2 mRNAs, with higher
induction in the P cells than the M cells (lanes 2 and 6).
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Figure 15. Northern Blot Analysis of Human PAI-2 mRNA from
PC3-P and M Cells Treated with the conditioned Medium

Total RNAs were extracted from human prostate
carcinoma PC3-P and M cell lines after incubation with
different conditioned media. Lanes 1 and 5: control with
normal medium; lanes 2 and 6: treatment with lung
conditioned medium for 16 hours; lanes 3 and 7: treatment
with kidney conditioned medium for 16 hours; lanes 4 and 8:
treatment with spleen conditioned medium for 16 hours. The
RNAs were separated by electrophoresis through a 1% agarose
gel. The RNAs were transferred onto a Zeta-probe filter,
hybridized with the

32

P-labeled human PAI-2 insert, and

exposed to X-ray film.

.....

PC3-P CONTROL IN R.M .

I\)

PC3-P IN LUNG C.M.

(,,)

PC3-P IN KIDNEY C.M.

~

PC3-P IN SPLEEN C.M.

U1

PC3-M CONTROL IN R.M.

en

PC3-M IN LUNG C.M .

......

PC3-M IN KIDNEY C.M.

ex>

PC3-M IN SPLEEN C.M.

'.'

/\

C>

"'tJ

"'tJ

~

)>

c

I

)>

I-'
l\J

I-'

Chapter V
DISCUSSION

Constitutively High Expression of Different Proteases
in Cell Lines with Different ras-transformations

EJ/vHa-ras cells were produced by Bradley et al.,
(1986) by transforming NIH 3T3 cells with a chimeric ras
construct containing two activating mutations, at codons 12
and 59 (Gibbs, et al., 1984). RASlLeudel cells were similarly
developed by Bradley et al. (1986) by transfecting NIH 3T3
cells by an homologous yeast RASl sequence activated by the
substitution of a Leu at position 68 (analogous to position
61 in the mammalian Ha-ras sequence). Both cell lines were
shown to have very high metastatic potentials in a nude
mouse lung colonization assay (Bradley et al., 1986). In my
study I show that the EJ/vHa-ras cells express a similar
constitutive level of CL mRNA as untransformed NIH 3T3
cells, but a 5.4-fold higher constitutive level of the mRNA
for the protease uPA with compared with NIH 3T3 cells (Table
Leu
5). In contrast, RASl del cells show low levels of
constitutive uPA mRNA but a 4.4-fold higher concentration of
the mRNA for the protease CL when compared with NIH 3T3
122
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cells (Table 5).
Chromogenic substrate assays were used to study the
enzymatic activities of uPA and CL in these cells. The
substrate N-carbobenzoxy-L-Phe-L-Arg-7-aminomethylcoumarin
(Z-Phe-Arg-AMC) was used to assay for cathepsin L-like
activity (Mason, 1986; Baricos et al., 1988). The uPA
enzymatic activity was determined with the chromogenic
substrate S-2551, which measures the activity of plasmin
generated following uPA treatment of plasminogen. The CLLeu
like activity of the RASl del cells was found to be 3.8fold higher than in its non-transformed parental NIH 3T3
cells, whereas CL activity of the EJ/vHa-ras cells was only
1.6-fold higher than in the NIH 3T3 cells. The highest uPA
enzymatic activity was found in EJ/vHa-ras cells, and was
3.2-fold higher than in NIH 3T3 cells. The uPA enzymatic
Leu
activity of RASl del cells was only 80% of the NIH 3T3 cell
line. The enzymatic activities of the ras-transformed cell
lines are, thus, proportional to the different mRNA levels
found in these cell lines. The results showed that higher
constitutive levels of either uPA and CL are associated with
cells transformed with the EJ/vHa-ras or RASlLeudel cells,
respectively.
The concentrations of CB mRNA has also been measured
with the slot blot assay. The result is not as dramatically
different as CL and uPA among the different ras transformed
cell lines. The highly metastatic

EJ/vHA-~

only had a 1.9-
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fold increase in CB mRNA over NIH 3T3 cells. The highly
metastatic RASlLeudel cell had a 1.5-fold increase in CB mRNA
above NIH 3T3 cells. Thus, the contribution of CB may not be
a major factor affecting the tumor metastatic potentials of
these cell lines.

Different Responses of ras-transf ormed Cell Lines to

PMA

The gene expressions of the proteases are affected in
vitro by many hormones, growth factors, and phorbol ester
{Sloane et al., 1987; Markus, 1988). There has been very
little research comparing the differential expressions of
proteases in cell lines derived from same parental cell line
and transformed with different oncogenes. It is a part of
the hypothesis of this project that the proteolytic
activities of tumor cells may be modified in vivo by signal
factors, and different oncogene transformation may lead to
different responses to the signal factors.
As it is currently impossible to study how the
protease activities are actually regulated in vivo by signal
factors, phorbol-12-myristate-13-acetate (PMA), a
diacylglycerol (DAG) analog, was used to activate the
protein kinase C {PKC) in the inositol phosphate signal
pathway (see Literature Section). The PKC pathway is one of
the major signal transduction pathways used by exogenous
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signal factors and the pathway is presumed to be utilized by

in vivo signal mechanisms.
Subconfluent cultures of cells were treated with 20

nM PMA and the total RNA was isolated by standard techniques
at o, 2, 4, 8, 16 and 32 hours. The variations of protease
mRNA levels at these time points were determined by a slot
blot technique. On PMA treatment, increases in uPA mRNA
levels occur in the EJ/vHa-ras and EJ-ras transformed cells
as well as untransformed NIH 3T3 cells. In contrast, there
was no induction of uPA mRNA in cells transformed by the
Leu
Leu
yeast RASl del sequence or the yeast HYB c
sequence. Thus
RASlLeudel transformations appear to suppress the normal PMA
induction of uPA mRNA, which is stimulated in EJ-ras and
EJ/vHa-ras transformed cells and untransformed NIH 3T3
cells.
Recently, Givol cloned (Givol, et al., 1992) three
ras genes with different mutations at codon 12 into the same
vector and used these ras oncogenes to transform chick
embryo fibroblasts. When the clones were introduced into
chick embryo, three types of organ specificity of the
metastatic tumors were observed, which were dependent on the
amino acid substitution at codon 12. The outcome of this
project correlates with this organ-specific metastasis
experiment. Every organ has its specific signal factors
profile, which may cause a diverse protease and protease
inhibitor expression among the cells transformed with
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different ras oncogenes.

Both constitutively High Protease Levels and PMA
Response Are Mainly Due to Changes in Transcription
Rate

In order to determine the mechanism of PMA
inducibility of uPA, CL and CB mRNA, a nuclear transcription
(run-on) assay was carried out. Without PMA treatment, the
CL transcription rate in RAS1 1 eu cells is 6-fold higher than
NIH 3T3 cells while the rate in EJ/vHa-ras cells is 2.5-fold
higher than NIH 3T3 cells. The uPA transcription rate of
EJ/vHa-ras cells is 7-fold higher than NIH 3T3 cells (Table
5). The results on the relative constitutive level of uPA is
also confirmed by Dr. Silberman in this lab with CAT assays
utilizing part of the 5' promoter region of the uPA gene as
an enhancer in a CAT vector with the a heterologous SV40
promoter. In these experiments, CAT activity was 7-fold
higher in EJ/vHa-ras cells than NIH 3T3 cells, while CAT
activity in RASlLeu transformed cells was equal to that in
NIH 3T3 cells (S. Silberman and R. M. Schultz, personal
communication). The difference in transcription rates of CL
and uPA in these cell lines are consistent with difference
observed in these cell lines in their mRNA levels and in
their levels of expressed enzymatic activities.
With PMA treatment for 2 hours, uPA transcription
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rate increased 4-fold in the NIH 3T3 cells, 3.6-fold in the
Leu
EJ/vHa-ras cells and only 10% in RASl
cells. In contrast,
a 2 fold PMA stimulation of CL transcription is observed in
RASl Leu cells. No stimulation by PMA of CL transcription is
observed in the EJ/vHa-ras or NIH 3T3 cell lines.
The results are summarized in the hypothetical scheme
of Figure 16 which displays independent pathways for
activated yeast RASl, activated mammalian-like ras, and the
PKC signal transduction pathway through non-activated
cellular p2lr~. PKC may control the activation of p2lr~ by
its down-regulation of GAP (Downward et al., 1990). c-Fos
and c-Jun are transcription factors activated by the
PKC/p21c-~ signal transduction pathway {Cai,

et al., 1990).

The scheme then depicts the results of this work:

(i) the

high constitutive expression of the uPA gene induced by
mammalian/viral EJ/vHa-ras transformation and the PMA
inducibility of uPA in mammalian ras-transformed (as well as
untransformed) NIH 3T3 cells,

(ii) the repression of PMA

induction of uPA transcription in cells transformed by
activated RASl sequences {HYB
cells),

cLeu

and RASl

Leu

del transformed

(iii) the high constitutive expressions and PMA

inducibility of CL and CB genes in HYB CLeu and RASlLeudel
transformed cells, and (iv) the lack of a PMA induction of
the CL gene in mammalian-like ras and untransformed NIH 3T3
cells.
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Putative Mechanisms for Differential Responses to
PMA in the ras-transf ormed Cell Lines

The dissimilar patterns of protease expressions inf er
the existence of at least two discrete signal transduction
pathways for Ras oncoproteins leading to alternate
phenotypes for the transformed state. The observation of
multiple pathways may be in agreement with the recent report
that more than one type of GAP protein can bind to the
effector site in Ras, and both GAPs are present in equal
amounts in NIH 3T3 cells (Bollag and McCormick, 1991; Vogel
et al., 1988). The increases observed in one or the other
pattern for protease expression, depending on the mutated
form of the ras oncogene, further shows the presence of
alternative compensating protease pathways which may exist
for the degradation of extracellular matrix during
metastasis even in transformed cells obtained from the same
parental cell line.
In humans, there are at least two genes encoding
proteins which stimulate the GTPase activity (GAP). One of
molecular mass 120,000 daltons is referred to as pl20GAP' and
the other NFl

GAP

(p280

type-1 gene. p120

GAP

GAP

.
) is encoded by the neurof ibromatosis

and NFl

GAP

,
proteins bind to the same

effector site in Ras, and it is the heterodimer of GAP-RASGTP
that is believed to transmit the downstream effector signal
from Ras (Martin et al., 1990; Bollag and McCormick, 1990).
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EJ/vHa-ras has an activating mutation at codon 12 while
RASlLeudel has an activating mutation at codon 68 (equivalent
to codon 61 in Ha-ras) . The affinity of the p120

GAP

has been

showed to increase significantly, when these mutations are
present. Accordingly, the affinity of pl20

GAP

may be better

to RASlLeudel with mutated codon at 68 as compared to its
binding affinity to mutated codon 12 in the EJ/vHa-ras. As
p120

GAP

and p280

GAP

,

have been shown to be present in

approximately equal concentrations in NIH 3T3 cells (Martin,
et al., 1990, Bollag and McCormick, 1990), it may be that
changes in amino acid codon from 12 (in EJ/vHa-ras) to codon
68 (in RASlLeudel) changes the relative affinities and thus
the type of the GAP effector associated with the respective
activated Ras protein. This putative change in the GAP
effector could cause the switching of the signal from one
biochemical pathway to the other. It is

possible that the

NFlGAP_Ras and the p120GAP_Ras complexes activate different
pathways for the transformation and generation of the
metastatic phenotype.
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Figure 16.

Hypothetical Pathways for Normal Ras and

Activated Mammalian and

Yeast Ras Regulation of Pro-

metastatic uPA, CL and CB Protease Genes.

Suppression of uPA induction by the PKC/p21°-~
pathway in yeast RASl-transformed cells shown by negative
symbol. Dotted line indicates the inducibility of CL and CB
genes by the PKC/p21°-~ pathway only in yeast RASl
transformed cells.
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Anti-sense Oliqonucleotides can Partially Inhibit
uPA and CL Enzymatic Activities in A Transient
Manner

Advances in molecular biology and synthetic chemistry
over the past two decades have stimulated research into the
use of antisense oligonucleotides as potential therapeutic
and research agents (Rothenberg et al., 1989). Although some
limitations, such as short half-lives in vivo and
cytotoxicity, prevent the use of unmodified oligonucleotide
as therapeutic agents, there are still reports of successful
applications to influence the expression of a given gene of
interest. For example, Zamecnik et al. (1986) and Goodchild
et al. (1988) demonstrated inhibition of HIV replication
upon addition of antisense oligonucloetides targeted against
viral mRNA. studies by Wickstrom et al. (1988) and Holt et
al. (1988) demonstrated repression of HL60 cell
proliferation and c-myc expression following addition of
antisense oligonucleotide directed against human c-myc mRNA.
Oligonucleotides complementary to c-myb-encoded mRNA was
shown to inhibit normal human hematopoiesis in vitro (Geirtz
and Calabretta, 1988) and proliferation of human myeloid
leukemia cell lines (Anfossi et al., 1989). An antisense
oligonucleotide to basic fibroblast growth factor repressed
proliferation of human malignant melanomas (Dorothea et al.,
1989). No general tenet for prediction of the effectiveness
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of a given oligonucleotide has been suggested. The process
seems to be system- and sequence-specific. In this work,
three 21-mer deoxyoligonucleotides was prepared: sense-uPA
(5'-ATGAAAGTCTGGCTGGCGAGC-3'), anti-uPA (5'GCTCGCCAGCCAGACTTTCAT-3'), and anti-CL (5'CAAAAGGAGTAAAAGATTCAT-3'). Anti-uPA and anti-CL were
prepared in an antisense direction (3' -> 5') of the first
21 nucleotides from the 5' start of translation in the mRNAs
for murine uPA and CL, respectively. NIH 3T3 cells, and EJ10

vHa-ras- and RAS1 udel-transformed cells were incubated with
100 uM of these oligos in the media containing 10% FBS for
24 hours. The oligo containing culture media was removed and
replaced with the oligo-free, serum-free medium. The CL and
uPA activities produced by the cells were tested in the
serum-free medium. The assay became impossible after 48
hour, as majority of the cells became detached from the
flasks in the cell culture. Enzymatic activities of uPA and
cathepsin L were determined by chromogenic or f luorogenic
substrates as described in methods.
In contrast to our expectations, the non-chemically
modified oligonucleotides significantly inhibited the
respective gene expressions, even if just in a transient
manner. Accordingly the synthesis of s-oligos was not
required. In both

EJ/vHa-~

and RASl

Leu

del-transformed cell

lines, anti-sense uPA selectively inhibited 44-49% of uPA
activities up to 48 hrs; and anti-sense cathepsin L
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selectively inhibited 33-39% of the CL enzymatic activities
up to 24 hrs. The different durations of inhibition may be
related to the different abundance of the uPA and CL mRNA
inside the cells.

Lunq Colonization Assay

To measure the effect of anti-sense oligonucleotides
one metastatic potential, nude mouse lung colonization
assays were employed. The ras-transformed cells were treated
in vitro with the oligonucleotides described above for 24
hours, the oligo-treated cells were injected into tail veins
of nude mice , and 2 weeks later the animals were sacrificed
and the tumor nodules on the lung counted under a dissecting
microscope. This assay measures tumor cell extravasation
from the blood stream with invasion of basement membrane and
extracellular matrix, and then growth into pulmonary tumors.
If a change in the number of metastatic colonies is
evidence for the effect of the oligo on the metastatic
process, it is important that the method for determining the
number of metastatic colonies be accurate and reproducible.
As stated by Fidler (1978), and discussed in the references
therein, most lung tumors in mice appear on the surface and
can be counted with a dissecting microscope.
There is some variation in the number of metastases
between control groups used in different experiments, but
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they are not statistically different. The variation probably
results from using cells maintained in culture for different
lengths of time as well as the use of different batches of
mice. As a valid control group was utilized with each
experimental group, the dissimilarity in the number of lung
colonies between different control groups carried out on
different days with different lots of mice, should not
affect the conclusion of the project.

Anti-sense Oligonucleotides can Selectively Decrease
Tumor Metastatic Potential in Particular Cell Lines.

As noted above, uPA and CL was shown to be more
highly expressed in EJ/vHa-ras and RASl Leudel transformed
cells, respectively. Expressed enzymatic activities of uPA
and cathepsin

L

were significantly inhibited by the 0-

oligonucleotide in a transient manner, as measured with
fluorogenic substrates. In both EJ/vHa-ras cell line and
RAS1 1 eudel cell line, anti-sense oligo inhibited at least 34%
of the enzymatic activities up to 24 hrs. The time course of
the initial arrest and invasion by tumor cells of an organ
in vivo, after tail vein injection, has been evaluated by
radiolabeling of a tumor cells with 1
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2-iodo-deoxy-uridine

(Fidler, 1978). The result showed the critical time in lung
colonization for cell adhesion and invasion is the first 12
to 24 hours after tail vein injection of the cells.
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Both uPA and CL have been implicated as enzymes
capable of much extracellular tissue destruction, including
the degradation of extracellular basement membrane. The
production of high levels of uPA and CL has been shown to
correlate with high levels of metastasis. Direct evidence
has shown that uPA plays a role in B16 melanoma metastasis
in C57BL mice (Yu and Schultz, 1990).
In this project, anti-sense oligo compounds have been
shown to be specific inhibitors of the proteolytic enzymes
cathepsin L and uPA

in

vitro. If uPA or CL is crucial to the

metastatic process in vivo in these cell lines, then
inhibition of the protease activities may lead to a
reduction of metastasis in a lung colonization assay.
Treatment of the cells with the anti-sense oligo prior to
injection of cells into nude mice would be expected to lower
the protease activities in the treated cells for at least 24
hours. Accordingly, the cells were injected immediately
after ceasing treatment with the anti-sense oligo. The
results were expected to give a clear picture as to the
importance of the particular protease in metastasis in vivo.
The nude mice experiments tests the hypothesis of the
selective involvement of proteases in different

~

transformed cells lines.
Experiment 1 utilized EJ/vHa-ras cells. The result
{Table 13) shows that the sense-uPA treated cells (control
oligo) produced an average of 130 tumors per lung. The anti-

137

CL treated cells gave an average of 122 tumors per lung,
which is not statically different from the control group.
The anti-sense uPA-treated cells produced an average of 41
tumors per lung, significantly below the control group (P <
0. 001) .
Experiment 2 used RASl

Leu

del cells. The results showed

that the sense uPA treated cells (control oligo) produced an
average of 94 tumors per lung. The anti-uPA treated cells
produced an average of 81 tumors per lung, not significantly
different from the control group. The anti-CL treated cells
produced an average of 26 tumors in lungs which was
significantly lower than the control (p < 0.01).
The latter work was repeated once more, the number of
tumors per lung was more variable than in the preceding
experiment (Table 14), but the anti-CL treated cells still
caused significantly fewer lungs colonies when compared with
the sense-uPA treated cells (P < 0.05 ).
Tumor metastatic potential does not appear to be
directly proportional to changes in the protease activity of
tumor cells. For example, anti-CL inhibits CL enzymatic
activity by 35% in RAS1 10udel cells, in which the total tumor
lung colonizations is reduced 70% with respect to the
controls group.
As CL inhibition in EJ/vHa-ras cells and uPA
inhibition in RAS1 10udel cells had no effect on lung
colonization ability, there may be a threshold amount of uPA
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or CL required for promotion of metastasis. CL concentration
,
, RASl Leud e l
in EJ vHa-ras ce 11 s an d uPA concent ra t ion
in

I

cells, respectively, may be too low to affect lung
colonization ability one way or another. Therefore,
inhibition of their already low respective activities had no
affect. On reaching a threshold level, metastatic ability
then becomes dependent on their relative amounts.
The results of the lung colonization assay with antisense inhibitors clearly show that metastasis can be
achieved with aid of alternative proteases. uPA and CL
proteases were separately induced by different ras oncogene
transformations. uPA and CL may compensate for one another
in tumor metastasis.

Direct Evidence for Involvement of CL in Tumor
Metastasis

Although an increase of CL has been reported to be
correlated with tumor metastatic potentials (Gottesman,
1988), this correlative evidence by its nature is an
indirect type of evidence. The specific inhibition of CL
synthesis by anti-CL and corresponding decrease in lung
colonization observed in this project is the first direct
evidence for a role of CL in tumor metastasis.
A problem in assigning a role to CL in tumor
metastasis is that CL is an acidic protease, its optimal pH
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for activity is 4. At neutral pH, which is the expected pH
of the extracellular space in the tumor invasion process, CL
enzymatic activities should be low. In addition, prior
evidence indicated CL was unstable at neutral pH, and thus
its activity will be predicted to last only a short time
(Gottesman, 1987). These properties of CL implied that CL
may not be a crucial enzyme in metastasis.
The doubts can be addressed in several ways. First,
CL is secreted as a proenzyme, which is stable at neutral
pH, and hence may be an excellent molecular vehicle for the
transfer of the protease in a cancer cell to the
extracellular environment. After secretion, procathepsin L
must be activated to its functional form. The mechanism of
activation is unknown. Secondly, even the mature form of
cathepsin L shows activity at neutral pH, albeit briefly
(Mason et al., 1987). In addition, CL could act in an acidic
microenvironment in the region of contact between the cell
surface and the extracellular matrix or basement membrane.
Secreted procathepsin L passes through the acidic
vesicles of the exocytic pathway in cancer cells. It might
act in this compartment to process, and perhaps activate,
cell surface receptors and secreted growth factors.
Increased amounts of cathepsin L in various intracellular
compartments, including the lysosomes of cancer cells, could
facilitate protein turnover during the growth of these cells
(Laumas et al., 1989). Cathepsin L could also be essential
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for the activation or inactivation of oncogene or antioncogene products or other intermediates in the process of
malignant transformation. In addition to a possible direct
role of cathepsin L in tumor metastasis, cathepsin L might
interfer with antigen processing with the potential ablation
of the immune response to tumors {Mouritsen et al., 1991).

PMA Induces More PAI-2 in Human Tumor Cell Lines with
Less Metastatic Potential

The activity of uPA can be regulated through control
of the amount of protease synthesized, or through the
production of its inhibitor(s). Some proteinase inhibitors
such as a2 -macroglobulin, al -proteinase inhibitor, and
antithrombin III inhibit a wide spectrum of proteases. As
their molecular weights are large and their activities are
non-specific in nature, these protease inhibitors are not
commonly thought to be of importance in precise control of
proteinase activity in tumor metastasis in vivo {Markus,
1988). However, there are at least two plasminogen activator
inhibitors (PAis) that bind PAs specifically, PAI-1 and PAI2. The pertinent information on these PAis have been
reviewed in the Literature Section.
The PC3-P and PC3-M cell lines are from a human
prostate carcinoma. The PC3-P {parental) cell line has a
significantly lower metastatic potential in the nude mice
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assay (Kozlowski et al., 1984), while the PC3-M cell line is
a derivative of the P line with a higher metastatic
potential (see Table 2).
A375-P & A375-SM cell lines are derived from a human
melanoma. A375-P cells show a low metastatic potential in
the nude mice assay, and A375-SM cells show a higher
metastatic potential than A375-P cells (see Table 2)
(Kozlowski et al., 1984).
Initial efforts to correlate uPA levels and tumor
metastatic potential in the PC3 and A375 cell lines failed
to detect any meaningful relationships. Attempts have also
been made to obtain a purposeful relationship between PAI-2
and tumor metastatic capability. However, no PAI-2 mRNA was
observed under basal conditions in these cells. However, on
treatment of these cell lines with PMA, both the PC3 and
A375 lines show observable increases of the uPA and PAI-2
mRNAs. In particular the less metastatic P lines make more
PAI-2 mRNA than the more metastatic M-line. The ability to
metastasize may thus correlate better with an increased
induction of PAI-2 mRNA levels in the P lines (parental, low
metastatic potential) than with an increase in urokinase
mRNA levels in the M lines (high metastatic potential). Data
showed that stimulation of uPA mRNA in PC3-M cells was only
20% (1.2-fold) over that of the PMA stimulation of urokinase
mRNA levels in PC3-P cells. In both the A375-P and M cell
lines, no uPA mRNA was observable even with PMA treatment.
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However, with PMA induction, both cell lines (PC3-P and
A375-P) with lower metastatic potentials produced much more
PAI-2 mRNA than those of their partners with high metastatic
potentials (PC3-M and A375-SM)

(6-fold higher in PC3-P, 16-

fold higher in A375-P). In addition, mRNA for a collagenase
inhibitor, TIMP, was also much more highly induced in the
A375-P than in the A375-SM cells (3-fold higher in A375-P).
Attempts were made to assay PAI-1 with a cDNA probe
for PAI-1 mRNA in these cell lines. No hybridization was
observed after extensive trials.
Although there are many prior studies on protease
inhibitors such as PAI-2 and TIMP, few reports have directly
connected PAI-2 with metastatic capacity of tumors until
recently. This work is among the first studies

correlating

the tumor metastatic potentials with the uPA inhibitors
levels as opposed to uPA itself. The significance of
difference in the inductions of PAI-2 for tumor metastasis
is not yet clear, as we have not yet shown that an antisense
oligonucleotide for PAI-2 can promote metastasis. However,
induction of PAI-2 in vivo in both cell lines is a likely
event and may occur through PKC. In addition, our data
implicates the importance of signal transduction pathways in
inducing both pro- and anti- metastatic promoting gene
expressions, and suggests an important role for protease
inhibitors in determining the metastatic potential of a
cell. The variations in PAI-2 levels may be more important
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than variations in urokinase levels in determining the net
urokinase activity and consequently the metastatic potential
of the cell lines PC3 and A375.

Superinduction of uPA by Cycloheximide

To test whether protein synthesis is required for the
effect of PMA on the PAI-2 mRNA level, PC3-P and M cells
were incubated for 24 hr with PMA, cycloheximide (CHX), and
a combination of the two compounds. Total RNAs were isolated
from the cells and analyzed by Northern blotting. Inhibition
of protein synthesis by CHX does not inhibit the induction
by PMA of uPA mRNA synthesis in these cell lines. Rather the
combination of PMA and CHX produces a 2.5-fold higher level
of uPA mRNA than PMA alone. Thus, cycloheximide leads to a
superinduction of uPA mRNA under PMA stimulation.
Superinduction of gene expression by incubation of
cultured cells with CHX as inducer has been described in a
variety of systems, such as superinduction of tPA mRNA in
isoproterenol-treated granulosa cells (Oikawa and Hsueh,
1989), PAI-2 in the human promyelocytic cell line HL-60
(Antalis and Dickinson, 1992), and the induction of uPA in
Hela cells (Novak et al., 1991). The exact mechanism(s)
underlying the superinduction by CHX in cells is unknown.
There are a few exOplanations for the marked accumulation of
uPA mRNA in the presence of PMA and CHX on the cells
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studied. The superinduction is probably not due to a
stabilization of uPA mRNA by CHX, as CHX alone did not
result in an increase in levels of uPA mRNA. However, in the
3 1 end of uPA a consensus AUUA sequence is found (Verde et
al., 1985), and this sequence has been shown to confer the
superinduction effect of CHX. The CHX effect might work on
protein(s) induced by PMA which modulate the increases in
the mRNA transcription rate normally observed with PMA
induction, or increase the uPA mRNA degradation rate. In
absence of the protein synthesis inhibitor, the full effect
of PMA induction is observed.

Conditioned Medium Induce More PAI-2 in Human
Prostate PC3-P Cells Than in PC3-M Cells

Considerable efforts has been made in this project to
study the different response of transformed cells to the PKC
activator PMA. As PMA is a compound isolated from a plant
and does not exist inside the body of animals, the data
based on PMA work is only a hypothesis. The idea needs to be
extrapolated to tumor metastasis in the animal. We do not
know, however, the identity of the signal factor(s) in vivo.
To try to find a signal factor(s) in vivo, a dozen

purified

growth factors and hormones that are commercially available
were utilized as a replacement of PMA in stimulation
experiments in cell culture. The factors studied were
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platelet-derived growth factor (PDGF), epidermal growth
factor (EGF), interleukin 1, interleukin 6, and nerve growth
factor (NGF). However, all these factors failed to produce
any stimulation of the proteases and inhibitors in the human
tumor cell lines PC3-P, PC3-M, A375-P and A375-SM. Finally,
the conditioned media from nude mice organ cultures were
collected, and used to culture these cell lines.
PC3-P and M cells were cultured with conditioned
media collected from lung, kidney and spleen of female nude
mice, and the RNA were isolated from these cells after 16
hr. uPA and PAI-2 cDNA were used as a probe in Northern blot
analysis of these cell lines. The astonishing result was
that treating PC3-P and M with the conditioned medium from
lung organ culture induced PAI-2 production in similar
pattern to that shown on PMA stimulation. No effect on PAI-2
mRNA induction was observed with any of the other organ
conditioned media. uPA mRNA is not significantly altered
with incubation of the conditioned media. Furthermore, these
cells only metastasized to the lung in nude mice assays of
the metastatic potential of these cell lines (Kozlowski et
al., 1984a, 1984b). The outcome shows there exist
stimulator(s) in lung, which can modify the protease
activities in similar fashion as does PMA in these cell
lines. Also, the effect is apparently on PAI-2 mRNA levels,
not on the uPA mRNA levels.
The nature of the stimulator existing in lung
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conditioned medium is unknown. The effect may be caused by a
single signal factor, or a combination of growth factor(s)
(Beutler and Cerami, 1986; Roberts et al., 1985).
Although similar observation was found with the
conditioned medium, the strength of the effector in the
conditioned medium was less than PMA (20 nM). This
conclusion was obtained from time length of film exposure in
Northern blot analysis required to achieve a similar density
of hybridization (data not shown). This may be due to both a
short half-life and/or the strength of the effector in the
conditioned media resulting in a less effective stimulation
than PMA in these experiments.

General Principle of Proteases Involved in Tumor
Metastasis

The increases observed in one or the other pattern
for protease expression, depending on the mutated form of
the ras oncogene, further indicates the presence of
alternative compensating protease pathways which may exist
for the degradation of extracellular matrix during
metastasis, even in transformed cells obtained from the same
parental cell line. The antisense oligo data show that in
one pathway uPA is an important facilitator of experimental
metastasis (lung colonization), while in the second pathway
CL facilitates experimental metastasis. A role for proteases
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in metastasis has long been suggested, but direct evidence
for a role of particular proteases has not been clear-cut.
In part, the confusion is due to the large amount of
correlative evidence from miscellaneous systems with
different proteases, which are often contradictory. Direct
evidence for a role of a particular protease in metastatic
processes only comes from the few experiments in which
selective inhibitors of proteases were utilized (Schultz, et
al., 1988), and from molecular biology experiments in which
particular protease gene expressions can be selectively
increased or decreased (Yu and Schultz, 1990). However, an
additional factor contributing to the confusion is the
possibility that an enzyme activity required for the
metastatic process in one tumor cell type may be not
required in another. This project show a reciprocal
variation for the importance of CL activity and uPA activity
in the different ras-transformed NIH 3T3 cells. The data
supports the hypothesis that different biochemical pathways
exist that generate different malignant phenotypes, even
within the same parental cell type that use a different set
of proteases to achieve metastasis. In addition, this
project obtained the first direct evidence for the
importance for CL in metastasis.
Although the complexity of proteases involved in
tumor metastasis is now appreciated, the result from this
project may contribute to some general principle in this
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field. Firstly, there is unlikely to exist a universal
protease produced by all cancer cells which can account for
the invasive and metastatic properties in cancer. Rather,
different cancers appears to employ different protease(s),
or combinations of proteases, to achieve the same end. The
decision as to which protease or proteases a specific tumor
type will use probably depends on the tissue of origin of
the cancer and the manner in which transformation is
achieved.
Secondly, differences in protease mRNA levels and
their activity observed in vitro may, or may not, be
reflective of the actual protease activity expressed by
those cells in vivo.

In vitro studies often fail to show a

correlation of protease activity with invasiveness in vivo.
Partial reasons for the bewilderment is that spectrum of
proteases observed in vitro in a tumor cell may be modified
in vivo. Possibly, the majority of observations in vitro
acquired up to now do not represent the true protease
activities actually involved in in vivo tumor metastasis.
Thirdly, the oncogenic mechanism causing increases of
protease activity is unclear. In some cases, increased or
decreased transcription of the protease gene may occur. In
other cases, gain or loss of activity of specific inhibitors
appears to contribute significantly to the activity of the
protease.
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As it is currently not possible to study how the
proteases activities are actually regulated in vivo by
signal factors, I studied phorbol-12-myristate-13-acetate
(PMA or TPA) which mimics diacylglycerol (DAG) in activating
the protein kinase C in the inositol phosphate signal
pathway.
To investigate the question related to mechanism of
transformation, I used a group of mouse cell lines
transformed by different ras oncogenes that show different
metastatic potentials in a nude mice assay system. NIH 3T3
cells are non-transformed mouse fibroblasts without
tumorigenic properties. The EJ-ras and EJ/vHa-ras cell lines
are NIH cells transformed by activated mammalian ras
Leu
Leu
,
oncogenes. Hyb c
and RASl del cell lines are NIH 3T3
cells transformed by yeast ras oncogene constructs.
By Northern and slot blots analysis of the RNAs for
mouse cathepsin B,

L

and urokinase, I studied mRNAs

expressed both constitutively and with phorbol ester
stimulation. These data show: 1) urokinase is at a
significantly higher constitutive level in the highly
metastatic EJ/vHa-ras line, but not in the highly metastatic
RASlLeudel cell line. 2) PMA stimulates urokinase mRNA in
untransformed NIH 3T3 and in the mammalian-ras transformed
cells, but did not stimulate urokinase mRNA in yeast
Leu
RASl del transformed cells. 3) CL mRNA is significantly
higher in highly metastatic RASlLeudel cell lines as compared
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with other cell lines. 4) PMA strongly induce CL mRNA in
yeast ras transformed HYB

cLeu

and RASl

Leu

•

del lines but PMA

does not induce CL mRNA in mammalian ras transformed cell
lines EJ/vHa-ras or EJ-ras.
RNA transcription rate (run-on) assays were carried
out which shows that the differences in mRNA levels for CL
and uPA with the different ras oncogenes are primarily due
to differences in transcription rates of the genes rather
than to differences in mRNA stability.
Based on the observation that urokinase is at a high
level and PMA inducible only in mammalian ras oncogene
transformed NIH 3T3 cells while cathepsin L is at a high
level and inducible only in the yeast ras transformed NIH
3T3 cells, I explored the possible roles of uPA and CL in
metastasis in these cell lines using oligonucleotide antisense inhibitors. Three 21-mer oligonucleotides were
selected based on published mRNA sequences for uPA and CL,
the sequences were designated sense-uPA (control), anti
-sense uPA, and anti-sense CL. I showed that the antisense
0-oligonucleotide can significantly inhibit CL and uPA
expressions in a transient manner. In both the EJ/vHa-ras
cell line and the RASl

Leu

del cell lines, anti-sense uPA

inhibited 45% of uPA activity up to 48 hours and anti-sense
CL inhibited 35% of the CL enzymatic activities up to 24
hours. Based on these results, we proceeded to nude mice
experiments to test the selective involvements of CL and
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urokinase in these cells lines.
EJ/vHa-ras cells were treated in vitro with the
oligonucleotides and injected into nude mice through their
tail vein. The anti-sense uPA significantly decrease the
metastatic potential of EJ/vHa-ras transformed cells
compared to control (p < 0.001). However, no effect of anti.

uPA was observe d with RASl

Leu

del cells. RASl

Leu

del cells

treated with anti-sense CL showed a significantly decrease
in experimental metastasis from the control group (P <
0.01). No effect of anti-CL on experimental metastasis was
observed on the EJ/vHa-ras cells. The nude mouse assay with
RASl

Leu

del cells was repeated more once, the anti-sense CL

group different significantly from sense-uPA group in this
repeat (p < 0.05).
The results demonstrated that high levels of uPA and
CL proteases are separately induced by different ras
oncogene transformations and uPA and CL may compensate for
each other in these two different metastatic pathways.
TWO pairs of cell lines isolated from human origins
were also investigated. PC3-P and M were isolated from human
prostate carcinoma (Kozlowski et al., 1984). A375-P and
A375-SM were from a human melanoma (Kozlowski et al., 1984).
Characterization by Fidler and co-worker showed that PC3-P
and A375-P exhibited a low metastatic potential, and PC3-M
and A375-SM have a higher metastatic potentials. I found
that uPA and its inhibitor, plasminogen activator inhibitor
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2 (PAI-2) are both induced with PMA in the P and M lines.
However, a more dramatic change of PAI-2 mRNA is observed,
whereas uPA mRNA levels do not vary as greatly. It appears
that the DAG analog (PMA) promotes the P cells to be less
metastatic by inducing more PAI-2 rather than inducing the M
line to be more metastatic by increasing uPA.
A Western blot was utilized to confirm the induction
of PAI-2 at the protein level. Without PMA treatment, there
is no PAI-2 observed by Western blot. After PMA induction,
PAI-2 protein is observed with much higher levels in the
PC3-P cells than in the PC3-M cells.
Cycloheximide, a protein synthesis inhibitor, was
utilized to study uPA induction by PMA. Cycloheximide
superinduced the uPA mRNA production triggered by PMA in
PC3-P and PC3-M cells.
I explored the differential response of PAI-2 in
vivo by using conditioned medium from the organs cultures of
nude mouse. PC3-P and M showed the increased mRNA production
of PAI-2 under the stimulation of lung conditioned medium.
There was a 5-fold greater stimulation of PAI-2 in the PC3-P
line than PC3-M line. Conditioned media from other organs
have no effect on PAI-2 mRNAs in these cell lines.
Some conclusion can be drawn from this project:
1. Transformation of different ras oncogenes can lead
to dissimilar metastatic phenotypes shown by diverse
protease expressions. Selective inhibition of UPA and CL
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showed that uPA is critical in one phenotype and CL in the
other phenotype.
2. Signal factors in vivo may modulate tumor
metastatic potential through regulation of the genes for
protease inhibitors rather than through regulation of the
gene for the proteases. Thus, in the PC3 cell lines, tumor
metastatic potential may be primarily modulated through
alteration of its PAI-2 activity.
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